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Abstract
Virtually every mammalian cell contains mitochondria. These double-membrane organelles continuously change
shape and position and contain the complete metabolic machinery for the oxidative conversion of pyruvate, fatty
acids, and amino acids into ATP. Mitochondria are crucially involved in cellular Ca2+ and redox homeostasis
and apoptosis induction. Maintenance of mitochondrial function and integrity requires an inside-negative po-
tential difference across the mitochondrial inner membrane. This potential is sustained by the electron-transport
chain (ETC). NADH:ubiquinone oxidoreductase or complex I (CI), the first and largest protein complex of the
ETC, couples the oxidation of NADH to the reduction of ubiquinone. During this process, electrons can escape
from CI and react with ambient oxygen to produce superoxide and derived reactive oxygen species (ROS).
Depending on the balance between their production and removal by antioxidant systems, ROS may function as
signaling molecules or induce damage to a variety of biomolecules or both. The latter ultimately leads to a loss of
mitochondrial and cellular function and integrity. In this review, we discuss (a) the role of CI in mitochondrial
functioning; (b) the composition, structure, and biogenesis of CI; (c) regulation of CI function; (d) the role of CI in
ROS generation; and (e) adaptive responses to CI deficiency. Antioxid. Redox Signal. 12, 1431–1470.
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I. Introduction
A. Mitochondrial structure and function
Mitochondria are motile organelles that not only pro-duce energy in the form of ATP, but also participate in
a number of intracellular processes such as the generation,
modulation, and propagation of cytosolic Ca2þ signals and
the control of life and death through apoptosis. In addition,
they are a continuous source of reactive oxygen species (ROS)
(4, 5, 31, 35, 73, 74, 83, 89, 113, 133, 154, 187, 211, 212, 282, 286).
Each mitochondrion consists of an ion-impermeable inner
membrane (MIM) that is enveloped by an ion-permeable
outer membrane (MOM; Fig. 1B–D). The latter permeability
arises from the presence of voltage-dependent anion channels
(VDACs) or ‘‘porins’’ (Fig. 2A). The mitochondrial double-
membrane system creates two mitochondrial compartments:
the matrix that is surrounded by the MIM and the inter-
membrane space (IMS) between the MIM and MOM.
The MIM is highly folded and protrudes into the matrix by
invaginations called cristae (Fig. 1B–D). As a consequence, the
MIM has a large surface area that increases the efficiency of
the chemical reactions occurring at its inner surface. The shape
of the cristae can range from tubular to lamellar, forming
small intracristal IMS compartments that open through nar-
row (10–15 nm) tubular membrane segments (cristae junc-
tions) into the large peripheral IMS compartment (171).
Evidence suggests that the topology of the MIM can pro-
foundly affect mitochondrial function by influencing the dif-
fusion dynamics of metabolites and freely diffusing proteins
(171). For instance, in isolated mouse liver mitochondria, re-
modeling of the MIM by tBID (truncated Bcl-2 interacting
domain) was shown to correlate with the mobilization of a
large fraction of the internal pool of cytochrome c (cyt-c; see
below), a small heme protein loosely associated with the IMS
side of the MIM (171). This remodeling involved a fivefold
widening of the cristae junctions, suggesting that diffusion of
cyt-c between intracristal and peripheral compartmentsmight
normally be rate limiting.
Mitochondrial size, shape, motility, and positioning within
the cell clearly reflect the metabolic state of the cell but also
depend on the type of cell, its cell-cycle phase and differen-
tiation stage, and its mitochondrial DNA (mtDNA) content.
Changes in mitochondrial functional state are often paralleled
by alterations in external appearance or internal structure or
both; the latter is associated with changes in matrix compo-
sition and physical properties (14, 110, 144, 145, 171, 181, 195,
298).Whether these alterations affectmetabolism, or vice versa,
remains to be firmly established (12, 14, 143, 145, 287). Even
within the same cell, mitochondrial appearance can vary from
punctuate to threadlike, and in some cell types, mitochondria
can form a large interconnected network (Fig. 1A) (12, 14, 63,
67, 119, 142, 143, 145, 169, 177, 287). Evidence has been pro-
vided (146) that mitochondrial size, shape, motility, and lo-
calization are related to the magnitude of the inside-negative
potential difference across the MIM (Dc; see below).
Net mitochondrial size and shape are controlled by the
balance betweenmitochondrial fusion and fission (63, 67, 119,
195). This continuous joining and splitting of mitochondria
may represent a mechanism for the exchange of content (e.g.,
proteins, lipids, and mitochondrial DNA) to preserve func-
tional integrity (14, 34, 143, 145). In mammals, three dynamin-
related GTPases are essential for mitochondrial fusion:
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mitofusin1 and 2 (Mfn1=2) and the optic atrophy 1 (OPA1)
protein (63, 67, 119, 195). Mitofusins induceMOM fusion after
docking of two juxtaposed mitochondria by the second Mfn
coiled-coil domain (59, 60). MIM dynamics and cristae re-
modeling involve OPA1, which normally resides in the IMS in
a MIM-associated form (195). MIM fusion depends on a suf-
ficiently negative Dc (67, 177), and thus, very likely on the
metabolic state of the mitochondrion. Fission of mammalian
mitochondria requires the action of the dynamin-related
GTPase Drp1 (dynamin-related protein 1). This protein is re-
cruited from the cytosol to the MOM, after which organelle
constriction occurs (63). The latter process is, at least in part,
mediated by direct or indirect interaction between Drp1 and
another MOM protein, hFis1 (human fission protein 1).
Most mitochondrial functions require a sufficiently large
Dc (191, 243). This potential difference is maintained by the
combined action of the four large protein complexes (CI to
CIV) of the electron-transport chain (ETC; Fig. 2A). As a first
step, electrons are abstracted from reduced nicotinamide
adenine dinucleotide (NADH) and reduced flavin adenine
dinucleotide (FADH2) at the matrix faces of CI (NADH:
ubiquinone oxidoreductase; EC 1.6.5.3) and CII (succi-
nate:ubiquinone oxidoreductase; EC 1.3.5.1), respectively.
NADH and FADH2 are formed during the oxidation of py-
ruvate, fatty acids, and amino acids. These fuels are trans-
ported from the cytosol into the mitochondrial matrix, where
they are used as carbon sources for the tricarboxylic acid
(TCA) cycle. Electrons are donated by CI and CII to ubiqui-
none or coenzyme Q10 (CoQ), which carries them to CIII
(ubiquinol:cytochrome c oxidoreductase; EC 1.10.2.2). In
principle, other enzymes also can donate electrons to the CoQ
pool: (a) the electron-transferring flavoprotein (ETF )-ubiqui-
none oxidoreductase, which is located on the matrix-facing
side of the MIM and transfers electrons generated during the
flavin-linked oxidation step in the catabolism of fatty acids;
(b) s,n-glycerophosphate dehydrogenase; and (c) dihydroor-
otate dehydrogenase, present only in some types ofmitochon-
dria (191). From CIII onward, cytochrome c (cyt-c) carries the
electrons toCIV(cytochrome coxidase;EC1.9.3.1).At the latter
complex, electrons react with molecular oxygen (O2) to form
water (H2O). In the liver, additional electrons are fed into the
ETCat cyt-cduring oxidation of sulfur-containing amino acids
by sulfite oxidase (191). However, this reaction usually occurs
at a very low rate when compared with other ETC inputs.
FIG. 1. Mitochondrial morphology and ultrastructure. (A) Mitochondria in a living primary human skin control fibroblast
(#5120), visualized by staining with the fluorescent cation rhodamine 123 and confocal microscopy. Within the same cell,
mitochondrial morphology ranges from large filaments to small spherical organelles. (B) Electron microscopy image of
perinuclear mitochondria in a primary human skin control fibroblast (#5120). The dotted lines surrounding the nuclear
membrane and the box indicate the magnified view in panel C. (C) Magnification of the box in (B) showing the mitochondrial
inner and outer membrane (arrows) and cristae (asterisks). (D) Schematic representation of mitochondrial compartmentali-
zation in four parts: the matrix, mitochondrial inner membrane (MIM), mitochondrial outer membrane (MOM), and inter-
membrane space (IMS).
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FIG. 2. The mitochondrial oxidative phosphorylation (OXPHOS) system. (A) Mitochondrial functioning depends on a
sufficiently large proton motive force (PMF ) across the mitochondrial inner membrane (MIM). The PMF consists of an
electrical (Dc) and a chemical (DpH) component and is maintained by the electron-transport chain (ETC). Functionally, the
ETC is composed of four multiprotein complexes (CI to CIV) and the electron carriers coenzyme Q10 (CoQ) and cytochrome c
(C). Electrons are extracted from NADH (at CI) and FADH2 (at CII) and transported by CoQ to CIII. Subsequently, electrons
are conveyed to CIV by cytochrome c, where they are donated to molecular O2 to form water. The energy released by the
electron transport is used to drive trans-MIM proton efflux, thereby establishing the PMF. By allowing backflow of protons,
adenosine 50-triphosphate (ATP) is then produced by the F0F1-ATP synthase (CV). The ETC complexes, together with CV,
constitute the oxidative phosphorylation (OXPHOS) system. For clarity, the mitochondrial outer membrane (MOM) is
shown, which contains voltage-dependent anion channels (VDACs) allowing ion exchange with the cytosol. (B) In addition to
CV-mediated ATP generation, the PMF also is required for transport processes across the MIM. These processes are (indi-
rectly) driven by either Dc or DpH. For instance, mitochondrial Ca2þ uptake, ATP=ADP exchange by the adenine-nucleotide
translocator (ANT), trans-MIM Naþ and Kþ fluxes (important in mitochondria volume regulation), and import of nDNA-
encoded preproteins are Dc dependent, whereas several mitochondrial antiporters (aspartate=glutamate, Hþ=Kþ, Hþ=Naþ,
2Hþ=Ca2þ) and symporters (Hþ=pyruvate and Pi=ADP) are DpH dependent. In this panel, indirect dependencies on DpH are
marked by dotted lines.
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The electrons start their journey through the ETCwith very
high energy. Crucially, they gradually lose this energy in a
controlled fashion as they pass along the ETC. This involves a
redox-potential span of 1.1 V, from the NADþ=NADH couple
to the O2=2H2O couple (see below) (191). The released energy
is used at three locationswithin the chain (CI, CIII, andCIV) to
expel protons from the matrix into the IMS, resulting in a
potential difference (Dc) and proton gradient (DpH) across
the MIM. The energy stored in this electrochemical proton
gradient, generally referred to as proton motive force (PMF ),
can be used for chemical, osmotic, and mechanical work. The
ETC reactions for CI (Equation I), CII (equation II), CIII
(Equation III), and CIV (Equation IV) can be summarized as
follows (91, 191, 243, 299):
NADHþubiquinone (Q)þ 5Hþmatrix ! NADþ
þubiquinol (QH2)þ 4HþIMS (I)
FADH2þubiquinone (Q)! FAD
þubiquinol (QH2) (II)
ubiquinol (QH2)þ 2 cyt-c (FeIII)
þ 2Hþmatrix ! ubiquinone (Q)
þ 2 cyt-c (FeII)þ 4HþIMS (III)
4 cyt-c (FeII)þ 8HþmatrixþO2 ! 4cyt-c (FeIII)
þ 4HþIMSþ 2H2O (IV)
The PMF is dominated by Dc, with DpH contributing*15%
to its total magnitude (146, 191, 243). This means that Dc can
be considered a key indicator of mitochondrial function,
health, and metabolic activity (68, 254). At complex V (F0=F1-
ATP-synthase or CV; EC 3.6.1.34), protons are allowed to
flow back into the mitochondrial matrix, thereby driving the
synthesis of ATP from ADP and inorganic phosphate (Pi).
This type of ATP synthesis is generally referred to as oxi-
dative phosphorylation (OXPHOS), in contrast to another
mode of ATP production known as substrate-level phos-
phorylation. In mammals, the OXPHOS system consists of 89
different subunits (239). For CI, CIII, CIV, and CV, these
proteins are encoded by both the nuclear DNA (nDNA) and
mtDNA, whereas CII solely consists of nDNA-encoded
subunits. Importantly, OXPHOS and oxygen consumption
are tightly coupled in healthy mitochondria (191, 252).
In addition to its crucial role in ATP synthesis, the PMF is
also used for a variety of other energy-dependent pro-
cesses. These processes are (indirectly) driven by either Dc or
DpH (Fig. 2B). For instance, mitochondrial Ca2þ uptake,
ATP=ADP exchange by the adenine-nucleotide translocator
(ANT), trans-MIM Naþ and Kþ fluxes (important in mito-
chondrial volume regulation), and import of nDNA-encoded
preproteins (see Section II.B) are Dc dependent, whereas
several mitochondrial antiporters (aspartate=glutamate,
Hþ=Kþ, Hþ=Naþ, 2Hþ=Ca2þ) and symporters (Hþ=pyruvate
and Pi=ADP) are DpH dependent (96, 136, 139, 141, 191, 196,
200, 243).
B. Tissue-dependent differences
in electron-transport chain expression
By using bovine heart, Scha¨gger and Pfeiffer (241) dem-
onstrated a ratio of complexes CI=CII=CIII=CIV of approxi-
mately 1:1.5:3:6 (see ref. 241 and the references therein).
Similarly, Lenaz and co-workers (161) demonstrated a ratio of
CI=CII=CIII=CIV=CV of 1:1.3:3:6.7:0.5 in bovine heart mito-
chondria. Detailed analysis of various rat tissues showed
molar ratios in CII=CoQ=CIII=cyt-c=CIV of 1:24:3:12:8 (heart),
1:58:3:11:7 (muscle), 1:58:3:35:8 (brain), 1:73:3:18:7 (kidney),
and 1:135:3:9:7 (liver) (11), revealing tissue-specific differences
in the relative amount of CoQ and, to a considerably lesser
extent, cyt-c, but not CII, CIII, and CIV. This finding may
suggest that the amount of CoQ is an important regulatory
factor of the flux of electrons through the ETC and, thus, the
cells’ mitochondrial energy production or OXPHOS capacity.
Further analysis of the rat tissues by the Rossignol group (11)
revealed tissue-specific differences in (a) the number of cris-
tae per surface unit (heart>muscle> brain> kidney> liver),
(b) the density of the mitochondrial matrix (heart> brain>
muscle> kidney> liver), (c) the maximal activity of citrate
synthase (heart>muscle> brain> kidney> liver), (d) the
amount of CI, assessed by determining the quantity of
NDUFA9, one of its nDNA-encoded subunits (see Section IC;
heart>muscle> brain¼ liver> kidney), (e) the maximal ac-
tivity of CIII (heart¼muscle> brain> liver> kidney), and (f )
the maximal activity of CIV (heart>muscle> brain>
liver> kidney). The amount of CIII core2 subunit, reflecting
ETC content, showed a strong positive correlation with citrate
synthase activity. Similarly, a strong positive correlation was
observed between the expression level of mitochondrial
transcription factor A (Tfam) and those of the NDUFA9
subunit of CI and the core2 subunit of CIII, illustrating the
balanced expression of the mtDNA- and nDNA-encoded
subunits of these two OXPHOS complexes (11).
Principal-component analysis of these data allowed clas-
sification of the tissues into three groups (11): (a) heart and
muscle, displaying highest OXPHOS capacity and a low re-
sistance against OXPHOS perturbation; (b) liver and kidney,
displaying a lower OXPHOS capacity and lower sensitivity to
OXPHOS defects; and (c) brain, which is intermediate be-
tween a and b with respect to OXPHOS capacity. Therefore, it
is to be expected that different tissues will display different
sensitivities to a pathologic defect of the OXPHOS system. An
in-depth discussion of the different types of ‘‘threshold ef-
fects,’’ as well as their molecular bases and the roles that they
play in the presentation of mitochondrial diseases, can be
found elsewhere (206, 224).
Comparison of rat heart, brain, and liver with respect to
the efficiency of mitochondrial energy production, reflected
by the ratio of ATP formation to oxygen consumption (P=O
ratio), revealed tissue-specific differences that were CI de-
pendent (53). This finding suggests that, depending on the
type of tissue, a smaller or larger part of the PMF is used for
processes other than the oxidative phosphorylation of ADP,
like the transport of ions or metabolites (see Section IA).
In conclusion, OXPHOS capacity varies significantly be-
tween tissues because of differences in amount, stoichiometry,
and maximal activity of its components and the use of the
PMF by systems other than CV. Therefore, it appears that the
ETC content is an important regulatory factor of the OXPHOS
capacity of the cells. Moreover, experimental evidence sug-
gests that individual OXPHOS complexes are assembled into
supercomplexes in the living cell (see Section IID), the stoi-
chiometry and spatial organization of which may also be in-
volved in the regulation of the OXPHOS capacity of the cells.
COMPLEX I: BIOGENESIS, REGULATION, AND ROS 1435
C. Composition, structure, and function of complex I
Human (Homo sapiens) and bovine (Bos taurus) CI consists
of 45 different subunits (Table 1) (39, 159), 14 of which are
essential for its catalytic function (30, 221). These 14 core
subunits consist of seven highly hydrophobic mtDNA-
encoded subunits (ND1, ND2, ND3, ND4, ND4L, ND5,
and ND6), and seven hydrophilic nDNA-encoded sub-
units (NDUFV1, NDUFV2, NDUFS1, NDUFS2, NDUFS3,
NDUFS7, and NDUFS8). Both human and bovine CI contain
31 additional (accessory) nDNA-encoded subunits, the func-
tion of which is largely unknown (Table 1). For convenience,
we use the human nomenclature for CI subunits throughout
this review, whereby ND stands for NADH dehydrogenase
and NDUF, for NADH dehydrogenase ubiquinone flavo-
protein.
The strictly aerobic yeast Yarrowia lipolytica has been ex-
tensively used to study CI composition, structure, and func-
tion (e.g., 30, 263, 299). In this model system, CI consists of
40 different subunits (Table 1). This compositional difference
with mammalian CI results from the fact that Yarrowia CI
‘‘misses’’ orthologues of 10 mammalian CI subunits
(NDUFV3, NDUFA4, NDUFA7, NDUFA10, NDUFB1,
NDUFB2, NDUFB5, NDUFB6, NDUFC1, and NDUFC2),
whereas it contains five additional proteins, which are ab-
sent in mammalian CI (ST1, NUZM, NUXM, NUNM, and
ACPM2). Subunit mass fingerprinting of mature Y. lipolytica
CI (180) revealed combined molecular masses of 274 kDa
(for the seven nDNA-encoded core subunits), 264 kDa (for the
seven mtDNA-encoded core subunits), and 403 kDa (for the
remaining nDNA-encoded accessory subunits). This equals a
predicted total molecular mass for the fully assembled com-
plex of 941 kDa. In mammals, a similar calculation yields a
total mass of 969 kDa, a value compatible with that obtained
by native gel electrophoresis (e.g., 65, 156, 267, 268, 289).
Electron-microscopy analysis of CI in mammals, yeast,
fungi, bacteria, and plants (i.e., B. taurus, Y. lipolytica, Neuro-
spora crassa, Escherichia coli, and Arabidopsis thalania) demon-
strates that it assumes an L-shaped conformation consisting of
a peripheral, matrix-protruding arm and a MIM-embedded
membrane arm of similar size (Fig. 3) (30, 76, 91, 103, 108, 218,
299). CI isolated from bovine heart was found to display re-
versible deactivation when incubated at 30–37oC (95). This
result suggests that CI may be present in an active and inac-
tive form in intact cells. Evidence was provided that the
transition between these two functional states of CI (the
‘‘active-inactive’’ transition) is associated with conformational
changes of or around the ND3 subunit. In this respect, che-
mical modification of cysteine-39 of the ND3 subunit pre-
vented transition into the active form and thereby effectively
inhibited complex I activity (95). In E. coli, the peripheral and
membrane arm widened on application of NADH, but not
NADPH, leading to an extension of the overall structure of the
complex (215). This suggests that CI redox reactions can in-
duce conformational changes. In its turn, nucleotide affinity to
the CI active site appears to be redox sensitive (107).
When purified bovine CI is dissociated in the presence of
chaotropic agents (i.e., N,N-dimethyldodecylamine N-oxide
and b-mercaptoethanol), it dissociates into two subcomplexes
(Ia and Ib) (87, 103). Subcomplex Ia harbors both hydro-
philic and hydrophobic subunits, including those that con-
tain flavin-mononucleotide (FMN) and the iron–sulfur (FeS)
clusters (30, 103, 233, 234). The hydrophilic part of Ia consists
of the flavoprotein (FP) fraction and the Il fraction, whereas
its hydrophobic part is designated the Ig fraction. Subcomplex
Ib contains only hydrophobic subunits that are embedded in
the MIM. From an evolutionary and functional point of view,
CI can be subdivided into three modules (Fig. 3) (30, 90, 299):
N (involved in NADH oxidation), Q (involved in CoQ re-
duction), and P (involved in proton pumping). A summary of
subunit localization in different subcomplexes as well as
functional classifications is provided in Table 1.
Fully assembled mammalian CI contains an FMN
(NDUFV1 subunit), which accepts electrons from NADH (23,
100, 106). These electrons are transported through the protein
by eight FeS clusters: N1a (NDUFV2), N1b (NDUFS1), N2
(NDUFS7), N3 (NDUFV1), N4 (NDUFS1), N5 (NDUFS1), N6a
(NDUFS8), andN6b (NDUFS8).Within these clusters, the iron
is coordinated with two to four cysteine side chains from the
polypeptide. In most FeS clusters (N2, N3, N4, N5, N6a, and
N6b), the iron atoms are coordinated to a total of four sulfur
atoms ([4Fe-4S]) in an approximately tetrahedral arrangement
(243). Two FeS clusters (N1a, N1b) display a [2Fe-2S] config-
uration. The iron atoms in each cluster form a conjugated
system, and instead of a single iron forming an Fe2þ=Fe3þ
redox couple, the entire cluster can lose or gain electrons (243).
Thus far, the mechanism that couples CI electron transport to
vectorial proton translocation remains incompletely under-
stood, although the NDUFS2 and ND1 subunits appear to
play a crucial role (184, 185, 299).
CI in the bacterium Thermus thermophilus (Table 1) contains
all the eight FeS clusters of the mammalian enzyme and an
additional one (N7), which is absent in mammalian CI (30,
116, 235, 236). Analysis of the 3.3-angstrom crystal structure of
the peripheral arm of this protein predicts a partial ‘‘pathway’’
for CI electron transport and suggests that electron channel-
ing through mammalian CI proceeds as follows (Fig. 3): FMN
(NDUFV1 subunit), N3 (NDUFV1), N1b (NDUFS1), N4
(NDUFS1), N5 (NDUFS1), N6a (NDUFS8), N6b (NDUFS8),
N2 (NDUFS7). Electrons are then transferred from FeS cluster
N2 to CoQ.
Data obtained with Y. lipolytica CI predicts that the total
length of this electron-transfer ‘‘wire’’ that connects NADH
oxidation and CoQ reduction equals*90 angstrom (299). The
T. thermophilus crystal structure further predicts that CoQ
binding occurs at subunits NDUFS2 and NDUFS7 (Fig. 4),
suggesting that these subunits are directly involved in elec-
tron donation to CoQ. A similar conclusion was reached in
Y. lipolytica, in which the proposed CI CoQ-binding cavity
was investigated by site-directed mutagenesis of the NDUFS2
and NDUFS7 subunits (263).
CI inhibitors act at the terminal electron-donating step of
CI, thereby inhibiting CoQ reduction. Based on kinetic data,
CI inhibitors were grouped into three classes, represented by
piericidin A (class I=A-type), rotenone (class II=B-type), and
capsaicin (C-type) (194). Of these inhibitors, the naturally
occurring plant alkaloid rotenone (a.k.a. tubatoxin, paraderil)
is most often used to study the effects of CI deficiency on
mitochondrial and cellular physiology (e.g., 8, 26, 45, 49, 142,
144, 163, 249, 250). Rotenone (C29H50O2) has been applied
in agriculture as an insecticidal, acaricidal (mite=spider kill-
ing), and piscicidal (fish killing) agent. The ‘‘LogP’’ value
(i.e., the octanol=water partition coefficient) of rotenone
equals 4.1 (source: pubchem.ncbi.nlm.nih.gov), suggesting
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that it is a moderately lipophilic molecule (for comparison:
the LogP value for the highly lipophilic vitamin E equals
10.7). Interestingly, 1-methyl-4-phenylpyridinium (MPPþ),
the bioactivated product of 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine (MPTP), also binds to the rotenone-
binding site, thereby inhibiting CI activity (8). The fact that
both rotenone and MPTP can induce Parkinson’s disease
in humans and rats suggests that CI deficiency might
play an important role in this disorder (8, 26). Binding-
competition experiments consistently demonstrated that all
Table 1. Complex I Subunits, Nomenclature, and Properties
Subunit designation in different speciesa
Homo sapiens Bos taurus
Yarrowia
lipolyticab
Thermus
thermophilus MW c Subd Predicted featurese
Experimental
featuresf
1: NDUFV1 51 kDa NUBM (N) Nqo1 51 Il=FP FMN, N3, MTS, Ac
2: NDUFV2 24 kDa NUHM (N) Nqo2 24 Il=FP N1a, MTS
3: NDUFV3 10 kDa – – 10 Il=FP MTS
4: NDUFS1 75 kDa NUAM (N) Nqo3 75 Il N1b, N4, N5, (N7),
MTS, Ac
5: NDUFS2 49 kDa NUCM (Q) Nqo4 49 Il MTS
6: NDUFS3 30 kDa NUGM (Q) Nqo5 30 Il MTS
7: NDUFS4 AQDQ NUYM – 18 Il pt, ps, MTS, P
8: NDUFS5 PFFD NIPM – 15 Ig
9: NDUFS6 13 kDa NUMM – 13 Il MTS
10: NDUFS7 PSST NUKM (Q) Nqo6 20 Il N2, MTS
11: NDUFS8 TYKY NUIM (Q) Nqo9 23 Il N6a=b, MTS
12: NDUFA1 MWFE NIMM – 7.5 Ig TM
13: NDUFA2 B8 NI8M – 8 Il Ac Ac
14: NDUFA3 B9 NIGM – 9 Ig TM, Ac Ac
15: NDUFA4 MLRQ – – 9 Ig=Ib Ac
16: NDUFA5 B13 NUFM – 13 Il Ac Ac
17: NDUFA6 B14 NB4M – 14 Ig Ac Ac
18: NDUFA7 B14.5a – – 14.5 Il Ps, Ac, P Ac, P
19: NDUFA8 PGIV NUPM – 19 Ig
20: NDUFA9 39 kDa NUEM – 39 Ig MTS, Ac
21: NDUFA10 42 kDa – – 42 Ig MTS, Ac P
22: NDUFA11 B14.7 NUJM – 14.7 Il TM Ac
23: NDUFA12 B17.2 N7BM – 17.1 Il Ac Ac, P
24: NDUFA13 B16.6 NB6M – 16.6 Il Proapoptotic, TM, Ac Ac, P
25: NDUFAB1 SDAP ACPM1 – 8 Ig=Ib Acyl carrier, pp, MTS
26: NDUFB1 MNLL – – 7 Ib TM
27: NDUFB2 AGGG – – 8 Ib MTS
28: NDUFB3 B12 NB2M – 12 Ib Methylated, TM, Ac Ac
29: NDUFB4 B15 NB5M – 15 Ig=Ib TM, Ac Ac, P
30: NDUFB5 SGDH – – 16 Ib MTS, TM
31: NDUFB6 B17 – – 17 Ib TM Ac
32: NDUFB7 B18 NB8M – 18 Ib Lipidation Ac
33: NDUFB8 ASHI NIAM – 19 Ib MTS, TM
34: NDUFB9 B22 NI2M – 22 Ib Ps, Ac, P Ac
35: NDUFB10 PDSW NIDM – 22 Ib Pt, P
36: NDUFB11 ESSS NESM – 17.3 Ib MTS, TM P
37: NDUFC1 KFYI – – 6 Ig=Ib MTS, TM
38: NDUFC2 B14.5b – – 14.5 Ib TM Ac, P
39: ND1 ND1 NU1M (P) Nqo8 35.7 Ig TM
40: ND2 ND2 NU2M (P) Nqo14 39 Ig=Ib TM
41: ND3 ND3 NU3M (P) Nqo7 13.2 Ig=Ib TM
42: ND4 ND4 NU4M (P) Nqo13 51.6 Ib TM
43: ND4L ND4L NULM (P) Nqo11 10.7 Ig=Ib TM
44: ND5 ND5 NU5M (P) Nqo12 67 Ib TM
45: ND6 ND6 NU6M (P) Nqo10 18.6 Ig=Ib TM
aCore subunits are in bold.
bThe predicted functional module to which the subunit belongs is given between brackets (N, involved in NADH oxidation;
Q, ubiquinone reduction; P, proton pumping). Data compiled from refs. 21, 71, 85, 103, 123, 124, 166, 180, 183, 203, 233, 244, 290, 297.
cMW is molecular mass in kDa.
dSub, Subcomplex (FP, Ia, Il, Ig) after detergent treatment (see text for details).
eGiven for the human subunits according to the UniProt database (http:==www.uniprot.org). pt, phosphothreonine; ps, phosphoserine; pp,
covalent phosphopantheitine; MTS, mitochondrial targeting sequence; TM, transmembrane domain(s); Ac, acetylation site(s);
P, phosphorylation site(s).
fEvidence obtained in Bos taurus for Ac and P.
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tested hydrophobic inhibitors of CI share a common bind-
ing domain with partially overlapping sites (194, 299).
Mutagenesis analysis and photoaffinity labeling studies of
Y. lipolytica, R. capsulatus, and bovine CI indicated that the
NDUFS2, NDUFS7, ND1, and ND5 subunits contribute to the
CI inhibitor–binding domain (30, 86, 187).
D. Isolated human complex I deficiency
Dysfunction of the OXPHOS system is associated with a
wide array of clinical manifestations, ranging from single le-
sions in Leber hereditary optic neuropathy (LHON) or mater-
nally inherited nonsyndromic deafness to more-widespread
lesions, including myopathies, encephalomyopathies, cardi-
opathies, or complex multisystem syndromes (69, 252).
OXPHOS malfunction also has been implicated in the path-
ophysiology of age-related diseases like Parkinson’s and
Alzheimer’s diseases, schizophrenia, bipolar disorder, Char-
cot-Marie-Tooth disease (CMT2K), Ohtahara syndrome,
neurogenic hypertension, metabolic syndrome, diabetes, and
certain forms of cancer (e.g., 15, 26, 40–42, 48, 64, 75, 89, 125,
148, 154, 181, 252).
Inherited disorders of the OXPHOS system are observed
once every 10,000 live births (69, 140). These disorders gen-
erally manifest themselves within 2 years after birth, and, in
the majority of cases (40%), OXPHOS dysfunction is associ-
ated with either a combined (15% of the cases) or isolated
(25%) deficiency of CI (69, 140, 251, 252). We recently pre-
sented an overview of the clinical, biochemical, and cell
physiological data of 15 children with isolated CI deficiency
caused bymutations in nDNA-encoded structural CI subunits
(69). Our findings point to a rather homogeneous clinical
picture in these children and illustrate the severity of the
disease. In extensive live-cell studies performed with long-
term rotenone-treated skin fibroblasts from healthy subjects
(healthy fibroblasts) and CI-deficient patients (patient fibro-
blasts), we uncovered important cell physiological features of
CI deficiency (see Section IV). A detailed overview regarding
the clinical features of (isolated) human CI deficiency, its pa-
thology, and possible treatment strategies falls outside the
scope of this review and can be found elsewhere (e.g., 15, 20,
30, 40–42, 64, 66, 69, 70, 83, 121, 140, 141, 145, 148, 160, 203,
204, 251, 253, 259, 261, 270, 286, 287). Below, we summarize
the current knowledge regarding CI biogenesis (Section II),
the role of CI in cellular reactive oxygen species (ROS) pro-
duction (Section III), and adaptive responses to CI deficiency
at the cellular level (Section IV).
II. Biogenesis of Complex I
A. Expression regulation of complex I
As a consequence of the limited coding capacity of the
mtDNA (*16,500 base pairs in humans) and the bigenomic
origin of four of the five OXPHOS complexes, all regulatory
factors that control the expression of nuclear and mitochon-
drial respiratory genes are of nuclear origin (Fig. 5) (237–239).
The mtDNA encodes for seven CI subunits (see Section IC),
one CIII subunit (cytochrome b), three CIV subunits (cyto-
chrome c oxidase subunits I–III), and two CV subunits (F0=F1-
ATP-synthase, F0 subunits 6 and 8). Additionally, it contains
the genetic information for two ribosomal RNAs (12S, 16S)
and 22 transfer RNAs (tRNAs) required for the mitochondrial
translation apparatus. Replication, transcription, and repair of
mtDNA and translation of mtRNA is controlled by a limited
number of nDNA-encoded proteins (239). These include,
among others, POLG (mitochondrial DNA polymerase g),
POLRMT (mitochondrial RNA polymerase), Tfam (mito-
chondrial transcription factor A), TFB1M (mitochondrial
transcription factor B1), TFB2M (mitochondrial transcription
factor B2), mTERF (mitochondrial transcription termination
factor), mtIF-2 (mitochondrial translation-initiation factor 2),
and the mitochondrial elongation factors mtEF-Tu, mtEF-Ts,
and mtEF-G. Expression of these factors is coordinated with
that of nDNA-encoded OXPHOS proteins through the action
of transcriptional activators and coactivators (238). These in-
clude the nuclear transcription factors NRF-1 (nuclear respi-
ratory factor 1), NRF-2 (nuclear respiratory factor 2), ERRa
(estrogen-related receptor a), and PPARs (peroxisome
proliferator–activated receptors), which are targeted by coac-
tivators of the PGC (peroxisome proliferator–activated recep-
tor g coactivator a) family, including PGC1-a, PGC1-b, and
PRC (PGC1-a related coactivator) (115). Expression of the
latter family is controlled by many external cues, like avail-
ability of nutrients, energy deprivation, and temperature (115,
239).
Classes of genes involved in mitochondrial biogenesis and
function that are targeted by NRF-1 and NRF-2 consist not
only of OXPHOS subunit and assembly genes, but also in-
clude shuttle and transporter genes, protein-import genes,
heme-biosynthesis genes, mtDNA replication and transcrip-
FIG. 3. Mammalian complex I structure and function.
L-shaped structure and proposed electron-transport path-
way of mammalian CI. After initial acceptation by FMN,
electrons are transported by Fe-S (N3, N1b, N4, N5, N6a,
N6b, N2) to the electron carrier coenzyme Q10 (CoQ) for
further transport to CIII. The energy released by the electron
transport is used to transfer protons from the mitochondrial
matrix across the mitochondrial inner membrane (MIM) into
the intermembrane space (IMS). The two ‘‘arms’’ or CI pro-
trude into the matrix (peripheral arm) and are embedded in
theMIM(membranearm). The smallerfigure, the size ofwhich
is indicated by the scale bar, shows the proposed functional
CI modules: N (involved in NADH oxidation), Q (CoQ re-
duction), and P (proton pumping). In this figure, the CI out-
line was taken from the bovine structure; the CI functional
domains reflect those in Yarrowia lipolytica, and the electron-
flow pathway was derived from Thermus thermophilus CI.
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FIG. 4. Crystal structure of the peripheral arm of complex I. The peripheral arm (see Fig. 3) was visualized by using a ‘‘tube’’
(left part) or ‘‘ball’’ representation (right part) based on the crystal structure of the CI peripheral arm in Thermus thermophilus
(2FUG; 116) by using Yasara software (152). Subunits were color coded and named according to human nomenclature
(‘‘NDUF,’’ see Table 1). The light blue subunit shown in the left panel (behind NDUFS1 and NDUFS3) represents a novel CI
subunit (Nqo15) in T. thermophilus, which is not present in mammalian CI. The NADH-binding domain is known to be present
on the NDUFV1 subunit. The T. thermophilus crystal structure predicts that CoQ binding occurs at subunits NDUFS2 and
NDUFS7 (right panel), suggesting that these subunits are directly involved in electron donation to CoQ. (For interpretation of the
references to color in this figure legend, the reader is referred to the web version of this article at www.liebertonline.com=ars).
FIG. 5. Regulation of complex I biogenesis. CI has a bi-genomic origin, with subunits encoded by both nDNA and
mtDNA. All regulatory factors that control the expression of nuclear and mitochondrial respiratory genes are of nuclear
origin. In this way, control is exerted at the level of mitochondrial protein import (TOM=TIM proteins), mtDNA replication,
transcription, and translation, and CI assembly. At the transcriptional level, environmental cues control the expression of
members of the PGC (peroxisome proliferator–activated receptor g coactivator a) family (e.g., PGC1-a, PGC1-b, and PRC),
which target nuclear transcription factors NRF-1 (nuclear respiratory factor 1), NRF-2 (nuclear respiratory factor 2), ERRa
(estrogen-related receptor a), and PPARs (peroxisome proliferator–activated receptors). Many genes involved in mitochon-
drial biogenesis and function are targeted by NRF-1 and NRF-2. These include CI subunit and assembly genes, mtDNA
replication and transcription genes, and mtRNA translation genes. All these proteins are imported into the mitochondrion by
dedicated translocases of the outer and inner mitochondrial membrane (TOM=TIM system). CI subunits encoded by the
nDNA (shaded ovals) or mtDNA (open ovals) are then brought together and, with the assistance of CI assembly proteins,
assembled into a functional CI. A detailed scheme of the CI assembly process is presented in Fig. 6.
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tion genes, and mtRNA-translation genes (238). More specif-
ically, NRF-1–recognition sites have been demonstrated on
nDNA genes encoding the NDUFS7 subunit of CI, cyt-c,
subunits of CII, CIII, CIV, CV, Tfam, TFB1M, and TFB2M.
NRF-2 sites were shown to be present on genes encoding
subunits of CII, CIV, CV, Tfam, TFB1M, and TFB2M (237).
Knockout-mouse models of mtDNA defects revealed in-
creased expression of nDNA-encoded proteins essential in
mtDNA replication or supply of nucleotides for DNA syn-
thesis (266). These proteins included ANT1 (adenine nucleo-
tide translocator 1 in the MIM), DGUOK (deoxyguanosine
kinase), HSP40 (mitochondrial heat-shock protein 40), MPV17
(a MIM protein), p53R2 (a ribonucleotide reductase subunit),
SSBP (single-stranded DNA-binding protein), TK2 (thymi-
dine kinase 2), TOPO (topoisomerase), and TP (thymidine
phosphorylase). Of these proteins, DGUOK, p53R2, TK2, and
TP play a role in the maintenance of the dNTP (deoxyribo-
nucleotide triphosphate) pool, whereas SSBP and TOPO, to-
gether with Tfam and Twinkle (a mtDNA helicase), bind
directly to mtDNA. It is currently unknown how MPV17 and
HSP40 function in mtDNA maintenance (266). Recent evi-
dence suggests that the action of STAT3, a member of the
STAT (signal transducer and activator of transcription) pro-
tein family, is required for optimal function of CI and the ETC
(284). Phosphorylation of STAT3 by the cytokine interleukin-6
induces activation of STAT3-responsive genes. STAT3 also is
present in mitochondria, and its knockout specifically re-
duced CI and CII activity. In agreement with these findings,
knockout of Tyk2, a JAK ( Janus kinase) family protein that
tyrosine phosphorylates STAT3, was shown to lead to defi-
ciencies in basal mitochondrial oxygen consumption, de-
creased cellular ATP levels, and impaired CI, CIII, and CIV
function in mouse primary pro-B lymphocytes (217). This
suggests that Tyk2-mediated phosphorylation of STAT3 is
required to sustain proper functioning of CI and the ETC.
B. Mitochondrial import of nDNA-encoded
complex I subunits
The vast majority of structural CI subunits (38 different
proteins) are encoded by the nDNA and, therefore, must be
imported across the MOM, IMS, and MIM. The classic im-
port pathway is guided by amino-terminal presequences (the
‘‘mitochondria-targeting sequence’’ or MTS). However, more
than 50% of all mitochondrial proteins do not use this ‘‘classic’’
import pathway but rather possess an internal mitochondria-
targeting signal (25). In the case of nDNA-encoded CI sub-
units, 18 of them contain a predicted MTS (including all core
subunits), whereas for the remaining 20 subunits, such an
MTS is absent (Table 1). Both nDNA-encoded precursor
proteins with and without an MTS are recognized by the
preprotein translocase of the mitochondrial outer membrane
(TOM-complex; Fig. 5). Next, MTS-containing peptides are
directed through a translocase of the mitochondrial inner
membrane (TIM) complex (TIM23-complex) and the motor
complex PAM (presequence translocase-associated motor) to
the mitochondrial matrix. Once the protein has been im-
ported, the MTS is cleaved off by the mitochondrial proces-
sing peptidase (MPP). When no MTS is present, precursor
proteins are recognized by the Tom70 receptor and translo-
cated by the TOMcomplex and the Tim9-Tim10 chaperones of
the IMS. Protein insertion in the MIM is then assisted by the
TIM22 complex. Detailed information on the mechanism and
protein machinery involved in mitochondrial protein import
falls outside the scope of this review and can be found else-
where (10, 22, 25, 179, 210, 256).
C. Assembly of complex I
After transcription, translation, and mitochondrial import,
the nDNA- and mtDNA-encoded CI subunits have to be
brought together for proper assembly of the functional com-
plex (Fig. 5). Information from phylogenetic and structural
databases indicates that particular CI subunits that have co-
evolved are arranged in very distinct structures, termed
modules (90, 268, 277, 279). Together, these modules consti-
tute the minimum CI structure required for catalytic function,
containing the 14 most-conserved subunits (see Section IC).
The proposed modules are the dehydrogenase module, con-
sisting of the NDUFV2, NDUFV1, and NDUFS1 subunits; the
hydrogenase module, consisting of the NDUFS2, NDUFS3,
NDUFS7, NDUFS8, ND1, and ND5 subunits; and the proton-
translocation module, consisting of the ND2, ND3, ND4,
ND4L, and ND6 subunits (65, 90, 156, 279). This classifica-
tion strongly resembles that of Brandt and co-workers (30),
in which an N-module (NDUFV1, NDUFV2, and NDUFS1), a
Q-module (NDUFS2, NDUFS3, NDUFS7, and NDUFS8),
and a P-module (ND-ND6 and ND4L) were proposed (see
Section IC).
According to the current assembly model (Fig. 6), CI bio-
genesis starts with the formation of an initial subcomplex
(Sub-1) containing at least NDUFS2 and NDUFS3. Most
probably, addition of NDUFS7, NDUFS8, and other proteins
(e.g., assembly factors) leads to formation of subcomplexes 2
(Sub-2) and 3 (Sub-3), which are thought to be MIM-associ-
ated (see below). Exactly how Sub-2 and Sub-3 are anchored
to the MIM is still unknown, but it might resemble that of CIV
subunits in Saccharomyces cerevisiae, the translation of which
was shown to occur at the MIM (189). In this yeast model
system, mtDNA-specific translational activator proteins, lo-
cated on the matrix side of the MIM, physically interact with
each other. The presence of such interactions suggests that
these activator proteins are organized at the inner surface of
the MIM in such a way that the synthesis of the three largest
CIV subunits (mtDNA-encoded Cox1p, Cox2p, and Cox3p)
occurs in a colocalized manner, thus facilitating the assembly
of the core of CIV (189). Recent experimental evidence (226)
suggests that also during CI assembly, mitochondrial trans-
lation is coupled to proteinmembrane attachment or insertion
or both (see Section IIC3).
Lipophilic mtDNA-encoded ND subunits are essential for
CI assembly to proceed beyond Sub-3 and the subsequent
formation of the subcomplexes 4 to 6 (Sub-4 to Sub-6) (277).
From there on, binding of additional subunits leads to the
formation of the fully assembled complex. This model is
compatible with CI assembly occurring in distinct steps,
during which subcomplexes of the membrane and peripheral
arm are assembled before being combined to form the fully
assembled complex (221, 268, 279). Evidence has been pro-
vided that, in addition to this de novo stepwise assembly, in-
dividual subunits can be exchanged from the fully assembled
complex (156, 157). Such a mechanism could facilitate
replacement of (oxidatively) damagedCI subunits ormodules
or both.
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Interestingly, by using a cell model for Leber hereditary
optic neuropathy (LHON), the most frequently observed
mitochondrial disorder caused by mtDNA mutations, it was
found that specific mtDNA polymorphisms modified the
pathogenic potential of the disease-causing mutations by
influencing the overall assembly kinetics of the OXPHOS
complexes (207). Further investigations are required to an-
swer the question whether nonpathogenic polymorphisms
also have an effect on the assembly or stability or both of these
complexes in healthy subjects.
Insights into the mechanism of CI assembly are obtained
largely from studies using Blue Native polyacrylamide gel
electrophoresis (BN-PAGE) of mitochondrial-enriched frac-
tions. Unfortunately, currently no complete set of proper an-
tibodies against CI subunits is available. Moreover, certain
assembly intermediates might have escaped detection be-
cause they are rapidly incorporated during CI assembly and
therefore have a short lifetime. Therefore, it is likely that more
CI assembly intermediates exist than those depicted in Fig. 6.
We recently applied submitochondrial fluorescence recovery
after photobleaching (FRAP) analysis to determine whether
CI assembly modules also exist within living cells (65). To this
end, we generated a collection of human cell lines with a
steady-state, low-level expression of CI subunits (NDUFV1,
NDUFV2, NDUFS3, NDUFA2, NDUFA12, and NDUFB6),
tagged with a monomeric variant of the Green Fluorescent
Protein (AcGFP1). These subunits were chosen in such a way
that they were part of the postulated dehydrogenase
(NDUFV1 and NDUFV2), hydrogenase (NDUFS3), and pro-
ton-translocation (NDUFB6) module of CI. In addition, two
accessory subunits (NDUFA2 and NDUFA12) were included
in the analysis. All subunits partially existed in a virtually
immobile fraction, likely representing their presence in holo
CI. Subunits were also detected either in a highly mobile
fraction (NDUFV1, NDUFV2, NDUFA2 and NDUFA12), re-
presenting matrix-soluble monomers, or in a slowly mobile
fraction (NDUFB6 and NDUFS3). In the case of the integral
membrane protein NDUFB6, the slowly mobile fraction most
likely consisted of one or more membrane-bound sub-
assemblies, whereas biochemical evidence suggested that, for
the NDUFS3 protein, this fraction existed of a mixture of
matrix-soluble and membrane-bound subassemblies. These
findings are in agreement with the idea that NDUFV1,
NDUFV2, NDUFA2, andNDUFA12 are incorporated at a late
FIG. 6. Complex I assembly model. The model is based on native gel electrophoresis of mitochondrial homogenates and
live-cell assembly analysis by using fluorescence recovery after photobleaching (FRAP) of cells expressing fluorescently
labeled CI subunits (see text for details). These approaches revealed the presence of several subcomplexes. CI biogenesis is
thought to be initiated by formation of a small subcomplex (Sub-1; containing the NDUFS2 and NDUFS3 subunits), to which
other CI subunits are subsequently added (boxes). MtDNA-encoded subunits are incorporated after formation of Sub-2 and
Sub-3. Individual CI subunits or CI functional modules or both might be exchanged with their counterparts that are already
incorporated in the subcomplex or fully assembled CI or both. Proper biogenesis and stabilization of CI (subcomplexes)
depends on the temporal action (horizontal bars) of assembly factors and interactions with other OXPHOS complexes (CIII and
CIV; see Fig. 7).
COMPLEX I: BIOGENESIS, REGULATION, AND ROS 1441
stage of the CI-assembly process, whereas the NDUFB6 and
NDUFS3 are incorporated at a much earlier stage (277).
In summary, our FRAP study supports the existence of
CI subassemblies within living cells in the mitochondrial
matrix and the MIM. Current experimental evidence indi-
cates that CI assembly requires assistance of at least seven
additional proteins, or assembly factors, which are subse-
quently discussed in more detail: NDUFAF1 (a.k.a. complex I
intermediate associated protein or CIA30), NDUFAF2 (a.k.a.
B17.2L, NDUFA12L or Mimetin), NDUFAF3 (a.k.a. C3orf60),
NDUFAF4 (a.k.a. C6orf66 or HRPAP20), C8orf38, C20orf7,
and Ecsit.
1. NDUFAF1. NDUFAF1 is an nDNA-encoded mito-
chondrial matrix protein that temporarily associates with CI
subunits during the earlier stages of CI assembly (78, 279). This
is illustrated by the observation that an NDUFAF1-deficient
patient was found to display serious defects in early CI as-
sembly, associated with increased CI-subunit breakdown.
The latter also suggests that CI subunits, if not incorporated in
a CI subcomplex, are prone to degradation (1, 78, 176).
Co-immunoprecipitation studies and immunodepletion
analysis revealed that NDUFAF1 associates with both newly
translated mtDNA-encoded subunits (i.e., ND1, ND2, and
ND3) and several nDNA-encoded subunits (78). Importantly,
the co-immunoprecipitates did not contain the NDUFS5
subunit. This subunit does not form stable intermediates and
is therefore believed to enter the CI-assembly pathway at a
relatively late stage (268). For that reason, the absence of any
NDUFS5 in the precipitates indicates that NDUFAF1 does not
associate with fully assembled CI (78). It was proposed that
NDUFAF1 acts during the initial assembly of a membrane
subcomplex that most likely contains ND2 and ND3. ND1
and other subunits then associate with this subcomplex
through separate module(s), finally to form a stable *830-
kDa intermediate. We recently demonstrated that Ecsit, a
cytosolic adaptor protein essential for inflammatory response
and embryonic development through the Toll-like receptor
and BMP (bone morphogenetic protein) signal-transduction
pathways, interacts with NDUFAF1 to control CI assembly
(278). It should be noted that NDUFAF1 also was found to be
present in large-molecular-weight complexes that did not
contain CI subunits, suggesting other roles for this protein as
well (78).
2. NDUFAF2. NDUFAF2 is a paralogue of theNDUFA12
accessory subunit of CI. NDUFAF2 does not associate with
fully assembled CI but appears to be specifically present in
an 830-kDa subcomplex, suggesting that it functions at a
late stage of CI assembly (193). Immunoprecipitation with
NDUFAF2 antibodies suggested an interaction with ND1,
NDUFV1, NDUFS1, NDUFS2, NDUFS3, and NDUFS4 but
not with NDUFA6 and NDUFA9 in human heart mitochon-
dria (193). Expression of NDUFAF2 was shown to be stimu-
lated by IL-1 and IL-6, acting through theMAPkinasepathway
to increase the transcription of a cytokine-responsive gene
(285). This result might explain the stimulatory effect of pro-
inflammatory cytokines on components of the respiratory
chain. In addition, yeast two-hybrid analysis indicated that
NDUFAF2 also may interact with a member of the microtu-
bule-associated protein family (MAP-1S). The latter protein
has been reported to interact with NADH dehydrogenase I
and cytochrome oxidase I and has been implicated in mito-
chondrial aggregation and nuclear genome destruction (285).
Finally, downregulation of NDUFAF2 significantly in-
creased caspase 3=7 activities after induction of apoptosis by
application of cycloheximide and TNF, whereas NDUFAF2
overexpression had the opposite effect. The latter results
clearly imply a role for NDUFAF2 in apoptosis.
3. NDUFAF3. Recent analysis of a cohort of 5 patients
with severe CI deficiency revealed that nDNA-encoded
NDUFAF3 is indispensable for the assembly of human CI
(229). The protein was shown predominantly (if not exclu-
sively) to localize to the mitochondrion. Although the protein
has no predicted transmembrane helices, it displayed a strong
interaction with the mitochondrial membrane. Native gel
electrophoresis followed by Western blotting revealed that
NDUFAF3 co-migrated with the CI-assembly intermediates
Sub 3, Sub 4, and Sub 5. In agreement with this result, tandem
affinity purification followed by mass spectrometry analysis
showed the presence of NDUFAF3 in protein associations
with NDUFAF4 (see below), NDUFS2 and NDUFS3, and,
most likely, NDUFS8 and NDUFA5, but not NDUFA9, ND1,
and NDUFA2. These results suggest that NDUFAF3 and
NDUFAF4 act in close cooperation from the early stages in the
CI-assembly process until formation of Sub 6 in the assembly
scheme (Fig. 6). Inhibition of mitochondrial translation re-
sulted in the disappearance of NDUFAF3 from Sub 3, Sub 4,
and Sub 5, whereas, in sharp contrast, NDUFAF4 was found
to accumulate in Sub 3. Based on these results, it is proposed
that NDUFAF4 bound to NDUFAF3 recruits an nDNA-
encoded early assembly intermediate, containing at least
NDUFS2 and NDUFS3, to form the MIM-bound Sub 3 inter-
mediate. Next, mitochondrial translation is required for
NDUFAF3 to remain attached to this intermediate and to al-
low assembly to proceed. The fact that the ancestor proteins of
NDUFAF3 are predicted to interact with the Sec membrane-
translocation machinery suggests that NDUFAF3 might
couple mitochondrial translation to protein membrane inser-
tion during assembly.
4. NDUFAF4. NDUFAF4 and NDUFAF3 cooperate dur-
ing CI assembly (see previous section). In muscle cells from
patients with an NDUFAF4 missense mutation, both the
amounts of NDUFAF4 and fully assembled CI weremarkedly
reduced (225). By using TargetP software, the first 34 residues
of the protein were predicted to form the mitochondrial-
targeting sequence. NDUFAF4 did not form an integral part
of the complex and was, therefore, regarded as a genuine CI-
assembly factor (225). NDUFAF4was previously identified as
a possible promotor of breast tumor cell invasion by inducing
the secretion of the extracellular matrix–degrading enzyme
MMP-9 (138). MMP-9 secretion is a calmodulin (CaM)-
dependent process, and it is tempting to speculate that the
action of NDUFAF4 in CI assembly is regulated by changes in
mitochondrial Ca2þ concentration.
5. C8orf38. C8orf38 was discovered by a large-scale
analysis of mitochondrial proteins (199). Two children with a
C8orf38 mutation displayed an isolated CI deficiency, sug-
gesting its involvement in the assembly or stability or both of
CI. Feature analysis of the C8orf38 protein suggests that it is
also involved in phytoene metabolism (i.e., it is a putative
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phytoene synthase), potentially implicating it in branched-
chain lipid metabolism (199).
6. C20orf7. C20orf7 is peripherally associated with the
matrix face of the MIM (257). Fully assembled CI was virtu-
ally absent in cultured skin fibroblasts from patients with a
C20orf7 mutation. It appeared that CI assembly was ham-
pered at an early stage, however, in a manner dissimilar to
that observed in patient fibroblasts carrying an NDUFAF1
mutation. This result is compatible with C20orf7 acting early
in CI assembly (Fig. 6). C20orf7 also has a predicted methyl-
transferase activity (257). It might, therefore, function to
methylate NDUFB3, which has been demonstrated to contain
two methylated, highly conserved, histidines (38).
7. Ecsit. Knockdown of Ecsit markedly reduced the
amount of fully assembled CI (278). In addition, it decreased
the amount of mitochondrial NDUFAF1, indicating that Ecsit
is required for maintenance of NDUFAF1 within this organ-
elle. Ecsit was demonstrated to co-migrate with NDUFAF1 in
three CI assembly intermediates of 500, 600, and 850 kDa.
Close inspection of the two-dimensional Blue Native SDS-
PAGE blots suggests that these bands do not contain NDUFS3
and ND1. Knockdown of Ecsit increased the amount of an
assembly intermediate that contained ND1 and NDUFS3 but
did not bind Ecsit or NDUFAF1 or both. This intermediate,
which was somewhat smaller than the previously mentioned
500-kDa intermediate, most likely represents Sub 4 or Sub 5 or
both (Fig. 6). The exact nature of the intermediates that bind
Ecsit and NDUFAF1 remains to be established. Knockdown
of Ecsit increased the levels of NAD(P)H, superoxide, and
cytosolic oxidants. Similar increases were observed in fibro-
blasts from CI-deficient patients (145, 273) and rotenone-
treated fibroblasts from healthy subjects (142, 272). As Ecsit
also constitutes part of the Toll-like receptor and BMP signal-
transduction pathways (292), it may play a role in coupling CI
assembly to inflammatory responses and embryonic devel-
opment.
8. Spatiotemporal dynamics of complex I assembly.
Although the current model (Fig. 6) suggests that CI assembly
might occur at dedicated sites of the MIM, the existence and
spatial distribution of such ‘‘assemblosomes’’ still awaits dis-
covery in vivo. It might even be the case that, within the same
cell, CI assembly takes place in only a subset of mitochon-
dria. A recent study investigated the distribution and dy-
namics of the E. coli cytochrome bd-I complex, a respiratory
terminal oxidase that resides in the cytoplasmic membrane
(162). By using video-rate epifluorescence microscopy and
total internal reflection (TIRF ) microscopy in combination
with FRAP, it was demonstrated that functional GFP-tagged
cytochrome bd-I complexes were concentrated in mobile do-
mains in the E. coli plasma membrane. This suggests that
respiration occurs in membrane patches containing multiple
‘‘respirasomes’’(see also Section IID), which are dedicated to
respiratory activity.
Another study addressed the dynamic distribution of
the NDUFS3 subunit of CI in living HeLa cells during
mitochondrial fusion and fission (34). It was found that GFP-
tagged NDUFS3 subunits displayed a heterogeneous ‘‘speck-
led’’ distribution after mitochondrial fusion, suggesting that
CI displays a specific localization with restricted diffusion
within the MIM. The latter is compatible with the existence of
distinctMIMsubcompartments for ETC complexes.However,
a far more homogeneously distributed fluorescence was ob-
served in HUVEC (human umbilical vein endothelial cell)
mitochondria (34), suggesting that the presence of localized
CI patches may depend on cell type or on metabolic state
or both.
In cells treated with a high concentration of doxycycline, an
inhibitor of mitochondrial translation, for 6 days, the amount
of fully assembled CI appeared to be reduced by *80%, in-
dicating that the half-life of the complex is relatively long
(268). After the removal of doxycycline, protein levels of the
fully assembled complex were restored again after 2–5 days.
Importantly, this rate of restoration does not necessarily re-
flect the time required for CI biosynthesis, because CI as-
sembly probably can make use of pools of already existing
subunits and partially assembled subcomplexes.
Analysis of human fetal tissue revealed that CI in heart,
liver, and muscle is fully assembled and functional at 11
weeks of gestation (178). Both mtDNA content and CI activity
were significantly increased in postnatal tissues. This result
is consistent with a switch from fetal, mostly anaerobic, gly-
colysis, to neonatal oxidative phosphorylation. In rat liver,
this switch was shown to occur within 1 h after birth and was
found to be paralleled by a marked increase in mitochondrial
biogenesis (202).
D. Supercomplex formation
Two simplified extreme models exist concerning the orga-
nization of the mitochondrial OXPHOS system: (a) that of
‘‘random organization’’ of the individual complexes (Fig. 7A),
and (b) that of a supercomplex assembly (‘‘respirasome’’)
formed by stable association of the individual complexes
(Fig. 7F ). It is possible that both models are valid and that free
OXPHOS complexes exist in equilibrium with supercom-
plexes, depending on the metabolic conditions of the cell (24,
43, 97, 241). Intermediate substrates of the respiratory chain
(i.e., cyt-c and CoQ) also appear to be functionally compart-
mentalized (13). Comparison of the unit stoichiometry of the
OXPHOS system in bovine heart mitochondria revealed a
ratio of CI=CII=CIII=CIV=CVof 1:1.3:3:6.7:0.5 and three to five
units of ANT (161). CI and CIII were shown to be rate limiting
in NADH oxidation, providing kinetic evidence for their
functional association. Similarly, CII was demonstrated to be
rate limiting in succinate oxidation, indicative of the absence
of any substrate channeling to CIII and CIV (19, 161).
Evidence has been provided for the existence of respira-
tory active supercomplexes in equilibrium with free com-
plexes in mouse liver (2). The proposed supercomplexes
included CI-CII-CIII-CIV, CI-CIII-CIV, CI-CIII-CV, and CII-
CIII-CIV (illustrated by Fig. 7B–E). Other studies revealed the
supercomplexes of CI-CIII-CIV, CI-CIII, CI-CIV, and CIII-CIV
in humans, yeast, plants, fungi, and bacteria (76, 77, 109, 173,
241, 280, 289, 290).
Regarding the stoichiometry of the supercomplexes, the
presence of the following species has been demonstrated in a
variety of organisms, including mammals (24, 241): CI-CIII2
(i.e., a single CI and a dimeric CIII), CIII2-CIV1-2, CI-CIII2-
CIV1-4, and CV2. Evidence in Neurospora crassa suggests the
existence of CI2, CI-CIII-CIV, and CIII-CIV supercomplexes
(173). In line with this, clear evidence for complex I dimers has
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been found in the fungus Podospora anserina (see ref. 167 and
the references therein) and Y. lipolytica (192).
As originally reported by the Scha¨gger group (see 241 and
the references therein), the vast majority of CI appears to be
present in supercomplexes (2). In bovine heart, for exam-
ple, 17% of CI existed in a CI-CIII supercomplex, and 63%, in a
CI-CIII-CIV supercomplex (98). This result is consistent with
the idea that CIII and CIV have a stabilizing effect on mam-
malian CI (1, 164, 242). In accordance with such a role of CIII
or CIV or both, CI was found to malfunction in CIV-deficient
Caenorhabditis elegans (258). Conversely, a reduction in the
amount of fully assembled CI and CIII was observed in pa-
tients with isolated CI deficiency caused by mutations in the
nDNA-encoded subunits NDUFS2 and NDUFS4, suggesting
that CIII, in its turn, is stabilized by CI (267). It should be
noted, however, that stabilization of CI in supercomplexes
might not be universal, because CIII and CIV appeared to be
dispensable for assembly or stabilization or both of CI in fungi
engineered not to express these two complexes (167). In ad-
dition to stabilization, other functional advantages proposed
for supercomplexes include catalytic enhancement, regulation
of respiration, guidance of cristae morphology, sequestra-
tion of reactive intermediates, increasing the protein insertion
capacity of theMIM and substrate channeling (19, 24, 98, 161).
In addition to OXPHOS supercomplexes consisting of com-
binations of CI, CII, CIII, CIV, and CV, structural evidence
suggests the existence of CV-containing ‘‘ATP synthasomes’’
in the MIM (44, 62). These ATP synthasomes contain CV, the
phosphate carrier (PIC), and the ANT in a stoichiometry of
1:1:1. Their existence supports a mechanism through which
mitochondrial ADP and Pi import, ATP synthesis, and ATP
export occur in a highly localized manner. It remains to be
established whether functional combinations of respirasomes
and ATP synthasomes exist in vivo.
E. Role of mitochondrial lipids in supercomplex
formation and complex I function and stability
CI activity was found to depend strongly on the phos-
pholipid content in a pure, monodisperse, and fully active
CI preparation from bovine heart mitochondria (248). It
was shown that the mitochondrial lipid cardiolipin (CL) was
tightly bound to CI, whereas phosphatidylcholine (PC) and
phosphatidylethanolamine (PE) bound much more weakly to
the complex. The activity of CI increased with the amount of
PC or PE binding or both, indicating the importance of these
lipids for CI function. Concerning CL, it was suggested that it
might be required for CI structural integrity and function
(248). CL furthermore interacts, often as a stimulatory cofac-
tor, with a variety of mitochondrial proteins, including the
phosphate, pyruvate, and carnitine carriers, the OXPHOS
complexes CII, CIII, CIV, and CV, CL-synthase, cyt-c, creatine
kinase, and the ANT (122, 245).
In the yeast S. cerevisiae, CL is required to link CIII and CIV
(241), suggesting that it also might stabilize CI in mammals.
CI-CIII-CIV and CI-CIII supercomplexes were less stable in
lymphoblasts from patients with Barth syndrome, expressing
reduced levels of mature CL (176). It was concluded that CL
stabilizes the interaction of CI and CIII, and therefore the re-
duced CI levels are a consequence of the less-stable CI-CIII
supercomplexes. This means that the supercomplex forma-
tion is necessary for CI assembly=stabilization, in line with
previous the data discussed in Section IID).
CL is found predominantly in the MIM and in the contact
sites between the MIM and the MOM (122). The amount of
CL in the MIM can alter because of changes in one or more of
the enzymatic steps involved in its biosynthesis or as a con-
sequence of its oxidative damage by reactive oxygen species
(ROS) (176, 209). Because CL is highly unsaturated (80%
linoleic acid) and present in close vicinity of ROS-generating
FIG. 7. Complex I as part of functional supercomplexes or
respirasomes. Simplified overview depicting possible mod-
els for the structural organization of mammalian oxidative
phosphorylation complexes and the electron carriers coen-
zyme Q10 (CoQ) and cytochrome c (C). This figure does not
consider the unit stoichiometry of the supercomplexes,
which is discussed in the text. (A) The ‘‘random organiza-
tion’’ model, in which no complexes are physically interact-
ing. (B) A supercomplex of CI-CII-CoQ-CIII-C-CIV and free
CV. (C) A supercomplex of CI-CoQ-CIII-C-CIV and free CV,
CII. (D) A supercomplex of CI-CoQ-CIII-CV and free CIV,
CII, C. (E) A supercomplex of CII-CoQ-CIII-C-CIV and free
CI, CV. (F) A supercomplex of CI-CII-CoQ-CIII-C-CIV-CV
(respirasome).
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ETC components (e.g., CI, see Section III), its susceptibility
to peroxidative attack is very high. Oxidative damage of
CL decreases the activity of CI (205). Interestingly, recent
evidence revealed that CL facilitates autoactivation of cas-
pase-8 by acting as an anchor at mitochondrial contact
sites (99).
F. Proteins interacting with complex I
In addition to indirect regulation of CI activity through
controlling its expression, incorporation into supercomplexes
and the lipid environment, direct regulatory interactions of
the mature complex with proteins and RNA have been re-
ported. For example, during human cytomegalovirus infec-
tion, a 2.7-kilobase virally encoded RNA binds to CI. This
interaction is essential for the maintenance of Dc and thus the
continued oxidative production of ATP, which is required for
the virus to complete its life cycle (220). The NDUFS1 subunit
of CI appears to be a critical mitochondrial caspase substrate
(222). When a noncleavable NDUFS1 mutant was used, Dc
and ATP levels were maintained, and the apoptosis-induced
increase in ROS levels was dampened. Moreover, although
these cells were dying and displayed cyt-c release and DNA
fragmentation, the mitochondrial morphology and plasma
membrane integrity were maintained. This suggests that
NDUFS1 cleavage by caspases is essential for several apo-
ptotic features to occur. Similarly, the NDUFS3 subunit is
specifically cleaved by the killer lymphocyte protease gran-
zyme A to induce superoxide generation and, ultimately,
apoptotic cell death (174).
A functional link between CI and hNOA1, the human
homologue of AtNOA1 (Arabidopsis thaliana nitric oxide as-
sociated protein 1), was proposed (262). Both overexpression
and knockdown of this MIM GTPase altered mitochondrial
morphology and ultrastructure. In addition, its knockdown
reduced mitochondrial O2 consumption in a CI-dependent
manner. Evidencewas provided that hNOA1 directly binds to
the structural CI subunits NDUFS3 and NDUFA9. Because
hNOA1 also interacted with DAP3 (death-associated protein
3), a protein involved in apoptosis, it was proposed that it
might play a role in connecting mitochondrial respiration and
apoptosis (262).
Serum response factor–binding protein 1 (SRFBP1) or
p49=STRAP, which is a cofactor contributing to the regulation
of SRF target genes in the heart, was shown to interact and
colocalize with the CI subunit NDUFAB1 (297). SRFBP1 is
found predominantly in the nucleus, and its overexpression
was shown to decrease the NADþ=NADH ratio, alter the
amount of NADþ, and increase the deacetylation of serum
response factor (SRF ). These results are compatible with a role
forp49=STRAP in tuningcardiac cell functionandmetabolism.
Interestingly, two CI subunits, NDUFV2 and ND6, were
identified as targets of calpain 10, a Ca2þ-activated cysteine
protease present in the MOM, MIM, IMS, and mitochondrial
matrix (7). Calpain inhibitors blocked Ca2þ-induced inhibi-
tion of CI, whereas overexpression of calpain 10 induced
mitochondrial swelling and autophagy that were blocked by
cyclosporin A, an inhibitor of mitochondrial permeability
transition (MPT). It was proposed that calpain 10 links dis-
turbed Ca2þ homeostasis to mitochondrial dysfunction
through the cleavage of CI subunits and the activation ofMPT.
CI also can be reversibly acetylated. This process is cata-
lyzed by protein acetyltransferases and deacetylases. Protein
acetylation occurs with acetyl CoA as donor substrate and
nucleophilic side chains as acceptors (281). Protein deacety-
lases are referred to as sirtuins or ‘‘silent information regula-
tor proteins’’ (71). Sirtuin action is NADþ dependent and,
classically, is required for the deacetylation of histones and
transcription factors involved in the regulation of survival
pathways, stress, andmetabolism (231, 232). Protein sequence
analysis predicts acetylation domains in 14 human CI sub-
units (NDUFV1, NDUFS1, NDUFA2, NDUFA4, NDUFA5,
NDUFA6, NDUFA7, NDUFA9, NDUFA10, NDUFA12,
NDUFA13, NDUFB3, NDUFB4, and NDUFB9; Table 1). For
bovine CI, it was demonstrated that the N terminus of 14
nDNA-encoded subunits was posttranslationally a-acetylated
(NDUFA2, NDUFA3, NDUFA5, NDUFA6, NDUFA7, NDU-
FA11, NDUFA12, NDUFA13, NDUFB3, NDUFB4, NDUFB6,
NDUFB7, NDUFB9, and NDUFC2) (38). Three mitochondrial
sirtuins have been identified (SIRT3, SIRT4, and SIRT5 (Fig. 8)
(6, 55, 112, 131, 165, 246, 247). Of these, only SIRT3 possesses
robust NADþ-dependent deacetylase activity. It has been
demonstrated that SIRT3 is proteolytically cleaved to its ac-
tive form (112). Hyperacetylation of mitochondrial proteins
was observed in SIRT3-deficient, but not in SIRT4- and SIRT5-
deficient, mice (165). SIRT3 deacetylates and thereby activates
acetyl-CoA synthetase (ACS2), isocitrate dehydrogenase 2
(ICDH2), and glutamate dehydrogenase (GDH), which all
reside in the mitochondrial matrix (246, 247). Functionally,
GDH is a central regulator of metabolism. Interestingly, the
SIRT3-sensitive isoform of ICDH2 catalyzes the formation of
NADPH (246). NADPH, in turn, is crucial for the regeneration
of antioxidants (170). Therefore, SIRT3-induced deacetylation
of ICDH2 offers protection against ROS (see Section IIIA2).
Recently, results obtained in SIRT3 knockout mice revealed
the involvement of SIRT3 in the maintenance of basal ATP
levels and regulation of mitochondrial electron transport (6).
It was found that, in the absence of SIRT3, multiple CI sub-
units displayed increased acetylation, leading to a specific
inhibition of CI activity. Moreover, basal ATP levels were
demonstrated to be decreased. Conversely, exogenous addi-
tion of SIRT3 restored CI activity and basal ATP levels. In-
terestingly, SIRT3 was demonstrated to interact physically
with the NDUFA9 subunit of CI. It was proposed that this
association plays a role in setting andmaintaining the optimal
ATP concentration. Because SIRT3 is an NADþ-dependent
deacetylase, it is tempting to speculate that NADþ, generated
by active CI, controls SIRT3 to modulate energy homeostasis
(Fig. 8) (6). SIRT3 also interacts with mitochondrial FOXO3a,
a protein belonging to the forkhead family of transcription
factors (131). Overexpression of SIRT3 induced the FOXO3a-
dependent expression of nuclear genes and increased the
amount of MnSOD. Conversely, overexpression of a deace-
tylation-deficient SIRT3mutant increased the levels of cellular
superoxide (O·2 ) and shifted the intracellular environment to
a more-oxidative state. These results suggest that when the
consumption of ATP decreases and, as a consequence, the
activity of CI and the levels of NADþ go down, the activity of
SIRT3 decreases, leading to increased acetylation of CI, ACS2,
ICDH2, and GDH and, thus, to a further decrease in CI ac-
tivity and a decrease in acetyl-CoA production and NADPH
formation, whereas it also leads to a decrease in MnSOD
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expression. Most probably, such a sequence of events reflects
a decreased production of O·2 and O
·
2 -derived ROS.
Not much is known about the mitochondrial function(s) of
SIRT4 and SIRT5. In pancreatic b cells, mitochondrial SIRT4
was shown to ADP-ribosylate GDH, thus decreasing its
activity (232). SIRT5 was demonstrated to localize to the IMS
or mitochondrial matrix or both (246). Functionally, SIRT5
showed no significant activity against GDH and ICDH2 but
readily deacetylated cyt-c. The physiological relevance of the
latter finding remains to be elucidated.
III. Complex I and Cellular ROS Generation
A. Mitochondria are an important
source of intracellular ROS
Mitochondria constitute amajor source of partially reduced
derivatives of molecular oxygen (O2). These reactive oxygen
species (ROS) include the superoxide anion (O·2 ), hydrogen
peroxide (H2O2), and the hydroxyl radical (OH·). It was esti-
mated that between 0.1 and 0.5% of the O2 consumed by
mitochondria is converted into O·2 (101). Apart from the
mitochondria, other enzyme systems also can generate ROS
(see Section IIIA2). Furthermore, ROS are produced by ex-
posure to ionizing and UV radiation and during the meta-
bolism of a wide spectrum of drugs and xenobiotics (288).
O·2 , H2O2, and OH
· are potent oxidants that readily extract
electrons from other molecules such as DNA, proteins, and
lipids, thereby altering their properties. Until recently, mito-
chondrial ROSweremostly associatedwith oxidative damage
and pathology. However, evidence is accumulating that they
also can function as regulatory molecules, thus playing an
important role in normal cell and organismal physiology.
A signaling role for reactive nitrogen species (RNS), such as
nitric oxide (NO·), is already well established (see also Section
IIIB3). Recently, in addition to three cytosolic NO· synthases
(NOS1, NOS2, and NOS3), a mitochondrial NO· synthase
(mtNOS) was identified (37). Reaction of O·2 withNO
·, which
occurs at diffusion-controlled rates (*11010M1·s1) (260),
leads to the formation of peroxinitrite (ONOO). Within mi-
tochondria, NO· andONOO are the predominant RNS (188).
ONOO-induced S-nitrosation of CI is discussed in more
detail below (Section IIIB3). However, an in-depth overview
of RNS and their roles in mitochondrial and cellular signaling
falls outside the scope of this review and can be found else-
where (37, 81, 94, 102, 260, 269).
1. Generation of O·2 . Mitochondrial O
·
2 production
occurs through CI and the TCA cycle enzyme a-ketoglutarate
dehydrogenase (a-KGDH) (4, 5, 54, 72, 84, 106, 117, 153, 155,
175, 264, 265). Because O2 is a relatively poor univalent elec-
tron acceptor (reduction potential Eh¼160mV), only good
univalent electron donors, such as mitochondrial CI,
can transfer an electron to it, leading to the formation of O 2
(149):
O2þ 1e ! O·2 (V)
The crystal structure of the peripheral arm of CI in
T. thermophilus (Fig. 4) reveals only two sites that are acces-
sible to O2, thus allowing the formation of O
·
2 : the NDUFV1
subunit, forming the FMN- and NADH-binding site of
the complex, and the CoQ-binding site (117). Experimental
evidence supporting this model was obtained in isolated mi-
tochondria (summarized in 187), demonstrating that CI gen-
erates large quantities of O·2 under only two conditions:
(a) when the FMN-binding site is reduced by the buildup of
NADH, and (b) when CoQ is reduced and DpH is high, a
condition that occurs during reverse electron transport from
CII to CI. Whether such reverse electron transport is of rele-
vance within living cells during nonpathologic conditions is
still unclear (5, 27, 72, 182). In fibroblasts from patients with
isolated CI deficiency, NADH autofluorescence and cellular
ROS levels increasedwith decreasing residual CI activity (272,
273). This result is compatible with the observation that an
increase in the NADH=NADþ ratio stimulates O·2 generation
by both CI and a-KGDH (5). Remarkably, however, these
FIG. 8. Mitochondrial sirtuins and regulation of complex I. Three mitochondrial sirtuins (nicotinamide adenine
dinucleotide–dependent protein deacetylases) have been identified (SIRT3, SIRT4, SIRT5). SIRT3 deacetylates and thereby
activates CI, acetyl-CoA synthetase (ACS2), glutamate dehydrogenase (GDH), and isocitrate dehydrogenase 2 (ICDH2). GDH
is a central regulator of metabolism, and ICDH2 catalyzes a key regulation point of the TCA cycle. Mitochondrial SIRT4
downregulates the activity of GDH. The ICDH2 isoform regulated by SIRT3 forms NADPH, which is thought to be im-
portant for NADPH-dependent regeneration of antioxidants (see also Fig. 11). SIRT3 physically interacts with CI, suggesting
that CI-generated NADþ might regulate SIRT3 to modulate energy homeostasis. SIRT5 localizes to the IMS or mitochondrial
matrix or both and deacetylates cyt-c.
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findings contrast with other experimental data showing that
inhibition of CI assembly by knockdown of NDUFA13,
NDUFS3 or the CI assembly factor NDUFAF1 reduced the
ROS production (125, 137).
Fluorescence-imaging microscopy of cultured primary
fibroblasts from a healthy subject loaded with (di)hy-
droethidium (HEt) or MitoSOX Red, which is designed spe-
cifically to target the mitochondrial matrix, revealed a marked
increase in cellular O·2 level with inhibition of CI by rotenone
(142). Both dyes are oxidized by O·2 , yielding fluorescent
products that accumulate predominantly in themitochondrial
matrix and the nucleus. Both short-term (10-min) and pro-
longed (72-h) rotenone treatment dose-dependently increased
the cellular O·2 level (Fig. 9A and B; solid circles). The O
·
2
level also increased after treatment with the CIII inhibitor
antimycin A (Fig. 9A and B; open circles). In contrast, CV
inhibition by oligomycin did not increase the O 2 levels (Fig.
9A and B; solid squares). Interestingly, long-term inhibition of
CI and CIII caused a shift in the dose–response curve toward
higher inhibitorconcentrations.This suggests that cellsbecome
less sensitive to the ETC inhibitors and=or O·2 -removing
systems are upregulated. Themaximal O·2 level reachedwith
prolonged treatment with rotenone, but not antimycin A, was
more than doubled as compared with that after short-term
treatment. It remains to be established whether this effect of
prolonged rotenone is somehow related to its stimulatory
effects on CI expression and mitochondrial length and degree
of branching (see also Section IVA). Together, these results
demonstrate that CI and CIII, but not CV, can generate
measurable amounts of O·2 in control human skin fibroblasts
when their catalytic function is inhibited.
Evidence in the literature suggests that mitochondrial ROS
generation is Dc-dependent (8, 29, 72) (Section IIIC2). How-
ever, ‘‘mild uncoupling’’ did not decrease mitochondrial su-
peroxide levels in cerebellar granule neurons (135). In healthy
fibroblasts, acute inhibition of CI by rotenone failed to detec-
tably alter Dc (Fig. 10C; second bar). Similarly, brief inhibition
of CV by oligomycin did not affect this parameter (Fig. 10E and
F; second bar), also not in combination with rotenone (Fig. 10E;
third bar). In contrast, brief inhibition of CIII by antimycin A
readily depolarized Dc (Fig. 10D; second bar). The presence of
neither rotenone (Fig. 10C; third bar) nor oligomycin (Fig. 10F;
third bar) influenced the effect of antimycinA onDc. The effect
of this inhibitor is dose dependent, because only a slight de-
polarization was observed with short-term treatment with a
relatively low antimycin A concentration of 100nM (68).
Summarizing these findings, it appears that CI activity is
not a major determinant of Dc and that O·2 generation is not
strictly coupled to Dc in cultured human skin fibroblasts.
2. Generation of H2O2. Within the mitochondrial matrix,
O·2 is rapidly dismutated into hydrogen peroxide (H2O2).
This process occurs either spontaneously (282) or through a
two-electron reaction catalyzed by the tetrameric mitochon-
drial Mn-superoxide dismutase (MnSOD or SOD2) (Fig. 11):
O·2 þO·2 þ 2Hþ !
MnSOD
H2O2þO2 (VI)
Importantly, the intramatrix concentration (3 to 10mM) and
reaction rate of MnSOD are very high (k¼ 2.3109M1·s1).
This suggests that the steady-state mitochondrial [O 2 ] is
low (29, 33, 187). In the cytosol, O·2 is rapidly dismutated by
FIG. 9. Effect of short- and long-term inhibition of ETC complexes on ROS-induced cellular ethidium (Et) formation.
(A) Dose-dependent effect of brief (10-min) CI inhibition by rotenone (ROT), CIII inhibition by antimycin A (AA), and CV
inhibition by oligomycin (OLI) on ROS-induced cellular ethidium (Et) formation in skin fibroblasts from a healthy subject
(#5120). Data points were fitted to a logistic model to determine the EC50 value, which is depicted next to the curve. OLI did
not stimulate Et formation, and therefore the dose–response relation was fitted by a straight line. (B) Same as in (A), but now
for prolonged (72-h) inhibitor treatment. For the ROT curve, no reliable EC50 value could be determined because no plateau
phase was reached. Similar to the short-term treatment in (A), OLI did not stimulate Et formation, and therefore the dose–
response relation was fitted by a straight line. In both panels, the average value obtained with vehicle-treated cells was set at
100%, to which all other values are related. Each data point is the average of >70 cells measured in at least two independent
experiments. Additional details about the experimental procedures can be found elsewhere (142, 272, 273).
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cytosolic CuZnSOD (SOD1). Depending on the cell type or its
functional state or both, H2O2 can also be formed by several
enzymatic systems present in different cellular compart-
ments, including (a) phagocytic oxidases and NADPH oxi-
dases at the plasma membrane; (b) mitochondrial P66Shc and
amine oxidase in the mitochondria; (c) sulfhydryl oxidase in
the endoplasmic reticulum; (d) amino acid oxidases, cyclo-
oxygenase, lipid oxygenase, and xanthine oxidase in the cy-
tosol; and (e) peroxisomal oxidases in the peroxisomes (37,
101, 269). Regarding peroxisomes, it is important to keep in
mind that these organelles contain the highest concentration
of catalase (CAT; see Equation VII), whereas mitochondria
have very low levels of this enzyme. Therefore, mitochondria
are regarded as the most important cellular source of H2O2
(37). Evidence was provided that the site of H2O2 generation
in brain mitochondria is altered by mitochondrial stress (111).
In E. coli, CI can directly reduce O2 to H2O2 (82), whereas in
most mammalian cell types, H2O2 is primarily broken down
by CAT and glutathione peroxidase (GPx):
H2O2þH2O2!CAT 2H2OþO2 (VII)
H2O2þ 2GSH!GPx 2H2OþGSSG (VIII)
H2O2 removal furthermore involves peroxiredoxin (Prx),
thioredoxin-2 (TRx), thioredoxin reductase-2 (TRxR), and
NADPH (Fig. 11). The GPx reaction is coupled to the glu-
tathione disulfide–glutathione redox couple (GSSG=GSH;
Eq. VIII). Glutathione (GSH or l-g-glutamyl-l-cysteinyl-
glycine) is part of the cellular nonenzymatic antioxidant
system, which also includes vitamin C (ascorbic acid), vita-
min E (a-tocopherol), carotenoids, and flavonoids (269).
Computational and experimental analysis revealed that the
rate of H2O2 removal depends on GSH (190). GSH is pres-
ent in high concentrations in the cytosol (1 to 11mM), nu-
cleus (3 to 15mM) and mitochondria (5 to 11mM) (57, 269).
Therefore, GSH is the predominant low-molecular-weight
thiol in animal cells and very important in the protection
against oxidative damage, both by direct reaction with ROS
and as electron donor for peroxidases (126). As a conse-
quence, the redox state of the GSSG=GSH couple is consid-
ered a prime indicator of the mitochondrial or cellular redox
environment or both (240). Although both the cytosol and
mitochondrial matrix are reducing environments, the thiol
redox environment in resting cells appears to be significantly
less oxidizing in the former than in the latter compartment
(272).
FIG. 10. Effect of acute inhibition of ETC complexes on the mitochondrial membrane potential. (A) Scheme depicting the
targets of the inhibitors used, which included CI (ROT, rotenone), CIII (AA, antimycin A; MYX, myxothiazol), and CV (OLI,
oligomycin). (B) Examples of typical experiments (individual rows) with fibroblasts from a healthy subject (#5120) stained
with the cation rhodamine 123 (R123; see (142) for experimental details). For each row, inhibitors were subsequently added to
the cells from left to right, as indicated. The R123 signal in the nucleus (region marked ‘‘N’’) was background corrected
(region marked ‘‘B’’) and used as a measure of Dc. The higher this signal, the less negative (more depolarized) Dc. (C–F)
Nuclear R123 fluorescence-intensity changes for the top to bottom experiments of (B). For each bar, the value presented is the
average SEM of the number of cells indicated (numerals). **Different from vehicle treated ( p< 0.01). ***Different from
vehicle treated ( p< 0.001).
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3. Generation of OH·. When [O·2 ] and=or [H2O2] be-
come too high to allow effective removal by mitochondrial or
cytosolic antioxidant systems, a situation referred to as oxi-
dative stress is reached. Oxidative stress often occurs during
pathologic conditions. In the worst-case scenario, ‘‘free iron’’
(Fe2þ) is released from [4Fe-4S] clusters. This might occur
directly from FeS-containing CI subunits or by O·2 -
induced liberation of Fe2þ from aconitase, a TCA-cycle
enzyme involved in the isomerization of citrate into isocitrate
through cis-aconitate, according to
[4Fe-4S]2þ þO·2 þ 2Hþ ! H2O2þ [4Fe-4S]3þ
! [3Fe-4S]þ þ Fe2þ (IX)
This one-electron oxidation of aconitase not only inactivates
the enzyme but also generatesH2O2 (288). Once released, Fe
2þ
can participate in the Fenton reaction, which leads to gener-
ation of the hydroxyl radical (OH·):
Fe2þþH2O2 ! Fe3þþOHþOH· (X)
The Fe3þ generated can react with O·2 to again yield Fe
2þ:
Fe3þ þO·2 ! Fe2þ þO2 (XI)
Overall, the combined reactions (X) and (XI) constitute an
intracellular Haber-Weiss reaction (269):
O·2 þH2O2 ! O2þOH þOH· (XII)
OH· is a very reactive ROS with a half-life (i.e., the time re-
quired to reduce its concentration by 1=e of the original con-
centration) of *109 s (101, 269). In addition, the reaction
between OH· and GSH has a very high rate constant (k* 1010
M1·s1) (288). This means that, once generated, OH· will
react in very close vicinity to its site of generation, as reflected
by its very low in vivo concentration of *1015 M (see also
Section IIIC).
B. Mitochondrial ROS as damaging or direct
regulatory molecules or both
During oxidative stress, ROS can directly modify lip-
ids, proteins, and DNA (18, 75, 80, 101, 269). Prime
FIG. 11. Role of complex I in cellular ROS homeostasis. Generation of O2 by complex I and the TCA-cycle enzyme
a-KGDH (a-ketoglutarate dehydrogenase) is stimulated by an increase in the NADH=NADþ ratio. O2 is subsequently
reduced to H2O2 and H2O by superoxide dismutase (SOD) and GPx (glutathione peroxidase), respectively. The GPx reac-
tion involves oxidation of glutathione (GSH) to GSSG and oxidation of reduced peroxiredoxin (Prx-red) to its oxidized form
(Prx-ox). Reduction of Prx-ox is coupled to the conversion of reduced thioredoxin-2 (TRx-red) into oxidized thioredoxin-2
(TRx-ox). TRx-ox is reconverted into TRx-red by thioredoxin reductase-2 (TRxR). The NADPH required for this reaction is
supplied by a DpH-dependent MIM transhydrogenase (TH) and ICDH2 (isocitrate dehydrogenase 2; see also Fig. 8). Simi-
larly, NADPH is used in the conversion of oxidized GSH (GSSG) into GSH by GR (glutathione reductase). Excessive O2
production stimulates hydroxyl radical (OH) formation. The latter radical induces the formation of carbon-centered lipid
radicals (L) from polyunsaturated fatty acids (LH). These, in turn, can form lipid peroxyl radicals (LOO), which are readily
degraded to malondialdehyde b-hydroxyacrolein (MDA) and 4-hydroxynonenal (4HNE). Formation of MDA and 4HNE is
counterbalanced by a cascade of antioxidant redox reactions (see text for details) (5, 74, 187, 269).
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mitochondrial ROS targets include lipids of the MIM and
probably also the MOM, subunits of the ETC complexes, and
mtDNA. These modifications are either irreversible (‘‘dam-
aging’’) because they cause molecule breakdown or reversible
(‘‘regulatory’’), thus leading to a temporary change in mole-
cule properties.
1. Lipid peroxidation. Mitochondrial lipids constitute an
important ROS target. Within a lipid environment, OH· ini-
tiates the formation of lipid radicals (L·) (Fig. 11). These lipid
radicals can react with O2 to form lipid peroxyl radicals
(LOO·). Reduction of these latter radicals involves a cascade of
antioxidant redox reactions, including vitamin E, vitamin C,
GSH, dihydrolipoic acid (DHLP), and NADPH (for details,
see 269). If LOO· is not properly reduced, it can lead to the
formation of malondialdehyde b-hydroxyacrolein (MDA) or
4-hydroxynonenal (4HNE) or both (208). Formation of the
latter, an a,b-unsaturated aldehyde, can induce protein car-
bonylation through Michael addition reactions with the side
chains of lysine, histidine, and cysteine residues (105). At the
ultrastructural level, elevated ROS levels have been associ-
ated with cristae dilation (171). However, clear indications
that ROS-induced lipid modification plays a role in this pro-
cess are lacking. Although it is tempting to speculate that this
widening of the diffusion pathways inside mitochondria is a
protective response, perhaps allowing faster efflux of ROS,
experimental evidence suggests that the reverse is true. Given
its sensitivity to oxidativemodification, CL is a prime target of
mitochondrial OH·. Within mitochondria, cyt-c is bound to
the outer surface of the MIM through its association with CL
(197). It has been demonstrated that enhanced ROS levels
increase the tendency for cyt-c release during apoptotic con-
ditions and, in addition, promote the opening of the mito-
chondrial permeability transition pore (PTP) (16, 187, 216).
These experimental results indicate that ROS-induced CL
oxidation may play a role in mitochondrial cyt-c release. In
cells with mutations in mtDNA-encoded CI subunits, the
voltage threshold for PTP opening is shifted toward resting
levels (216). This shift was sensitive to antioxidants, suggest-
ing that defective CI sensitizes the PTP through increased
ROS production. It remains to be established whether a sim-
ilar shift occurs in fibroblasts of patients with isolated CI de-
ficiency due to nDNA mutations, which were shown to
display significantly increased ROS levels (272, 273). As dis-
cussed in Section IIE, CL oxidation also affects CI activity and
ETC supercomplex formation.
2. Protein carbonylation. When an external OH·-
generating system was used to induce protein carbonyla-
tion in nonsynaptosomal mitochondria from rat brain, it was
found that rapid CI inactivation occurred when a certain
threshold was reached (9). In isolated mouse heart mito-
chondria and adult bovine heart submitochondrial particles
(SMPs), (age dependent) oxidative modification of specific
ETC subunits was already observed at resting conditions by
using immunoblotting and mass spectrometry (50,51). These
modifications included (a) carbonylation of CI (NDUFS1
subunit), CII (SDHA subunit), CIII (core 1 and 2 subunits),
CIV (subunit 4), and CV (a and b chains); (b) formation of
nitrotyrosine adducts of CI (NDUFV1 subunit), CIII (core 1
subunit), and CV (b chain); and (c) formation of 4HNE ad-
ducts of CI (NDUFS1, NDUFS2, NDUFA9, and NDUFB6
subunits), CII (SDHA subunit), CIII (core 1 and 2 subunits and
cyt-c1 subunit), CIV (subunits 4 and 4b), and CV (a and b
chains). In addition, 4HNE formed adducts with VDAC and
ANT. For ETC complexes, it has been demonstrated that these
modifications reduced their activity in vitro. Taken together,
the latter results show that ETC electron leakage and subse-
quent ROS formation also occur under physiologic condi-
tions, thereby causing specific modifications of ETC subunits
that possibly contribute to the progressive mitochondrial
dysfunction during normal aging (49).
During stimulation of pulmonary artery smooth muscle
cells with endothelin-1, ROS-induced protein carbonylation
levels increased at first and then decreased again, indicating
the presence of an active decarbonylation mechanism (291).
Cellular TRx levels were increased during the decarbonyla-
tion phase, and when TRxR was inhibited, decarbonylation
was suppressed. These results suggest that endothelin-1
promotes oxidant signaling and, directly or indirectly, TRx-
mediated reductive signaling to regulate protein carbonyla-
tion and decarbonylation. It was proposed that ROS-induced
protein carbonylation might function as a novel signaling
mechanism triggered by ligand–receptor binding.
3. Protein disulfide formation and glutathionylation.
Many proteins contain free thiols that can potentially react
with ROS to form internal disulfides or mixed disulfides with
low-molecular-mass thiols (i.e., resulting from the interaction
of protein thiols with GSH). Protein disulfide formation and
glutathionylation are of significance in both reversal of oxi-
dative damage and redox signaling (57, 126–128). As far as CI
is concerned, this suggests that its cysteine residues might
participate in regulation of its expression and activity at both
normal conditions and pathophysiologic conditions of oxi-
dative stress (46, 126).When isolated bovine CIwas incubated
with NADH for 1 h at room temperature by using coenzyme
Q1 as an electron acceptor, O
·
2 -induced intramolecular dis-
ulfide formation at NDUFV1 cysteines (C125, C142, C187, and
C206) was observed (296). Another study revealed that
C531 and C704 of the NDUFS1 subunit in bovine heart were
specifically glutathionylated during conditions of oxidative
stress, whereas the four non–FeS-cluster cysteine residues
remained as free thiols (129). Although CI glutathionylation
decreased CI activity, it did not increase O·2 formation.
Moreover, reversal of glutathionylation led to restoration of
CI activity. It was concluded that C531 and C704 are impor-
tant in preventing CI oxidative damage.
NO· is known to inhibit mitochondrial respiration through
inhibitory S-nitrosation of CI, which is prevented by GSH
(52). In bovine heart mitochondrial preparations, ONOO
application reduced the activities of CI, CII, and CV by 50 to
80%, with less effect on CIV activity and no inhibition of
CIII (188). For CI, ONOO-associated modifications with a
3-nitrotyrosine signature occurred mainly with subunits
NDUFS2, NDUFS8, NDUFA6, NDUFA12, and NDUFB4. In
dopaminergic cells, short- and long-term depletion of cellular
and mitochondrial GSH resulted in increased oxidative stress
and decreased mitochondrial function (48, 134). It appears
that the conformational state of CI (i.e., the ‘‘active-inactive’’
transition described in Section IC) is relevant for its interaction
with nitrosothiols and ONOO (93).
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C. Mitochondrial ROS as signaling molecules
In addition to their direct regulatory effects, ROS may also
act as (indirect) signaling molecules (45, 56–58, 74, 101, 114,
130, 133, 145, 150, 168, 186, 219, 228, 255, 269, 271, 288, 291,
300). ROS have distinct physicochemical properties like
chemical reactivity and half-life (see later). In this respect,
O·2 and H2O2 have preferred biological targets, whereas OH
·
reacts indiscriminately with biological molecules (58). This is
illustrated by the mechanism of action of the redox-sensitive
E. coli transcription factors SoxR and OxyR. Based on its high
electrostatic attraction, O·2 displays a high atomic reactivity
toward FeS clusters that constitute the SoxR redox center
([2Fe-2S]). FeS clusters in other redox-sensitive molecules also
are sensitive to iron, oxygen, and reactive nitrogen species
(RNS) and, therefore, do not only specifically react with O·2 .
How O·2 -specificity is achieved in the SoxR system remains
to be determined (58). In case of H2O2, a specific reaction with
unique cysteine residues in the OxyR redox center occurs at a
high enough rate (k * 107 M1·s1) to be competitive in a
cellular environment (58, 288).
The function and=or expression of many proteins is indi-
rectly regulated by ROS or redox status (74, 269, 271). Ex-
amples include (a) transcription factors other than
SoxR=OxyR (c-Jun=c-Fos, OhrR, Hsf1, Nrf-2=KEAP-1, Bach 1,
AP1, NF-kb, HIF-1, JAK, p53, NFAT, and HIF-1); (b) kinases
( JNK, Sty1, MEKK1, ERK1=2, IKKbeta, Src family kinases,
human insulin receptor kinase, p27 kinase, p38 kinase, PKC,
and PKA); (c) phosphatases (LMW-PTPs, PTEN, Cdc25C, and
PTP1B); (d) ion channels [inositol trisphospate receptors
(IP3Rs), ryanodine receptors, and ATP-sensitive potassium
channels]; and (e) others (sarco=endoplasmic reticulum Ca2þ
ATPase (SERCA), RNase H1, and GAPDH).
Given the sensitivity of kinase signaling pathways to ROS,
in situ activation of mitochondrial kinases may represent a
potent reverse-signaling mechanism for mitochondrial auto-
regulation and communication of mitochondrial status to the
rest of the cell (120). The presence of kinases within thematrix,
MOM, MIM, and IMS has been demonstrated (3, 120, 151).
Mitochondrial kinase effectors include proteins involved in
apoptosis (Bad, Bax, Bcl-2, and Bcl-xL), ETC proteins (e.g., CI
and CIV), proteins involved in PTP opening (VDAC and
ANT), the mitochondrial ATP-sensitive Kþ channel (mito-
KATP), and phospholipid scramblase 3 (PLSCR3) (151).
Protein sequence analysis predicts that four human CI
subunits (NDUFS4, NDUFA7, NDUFB9, and NDUFB10) can
be phosphorylated (Table 1). Conversely, experimental evi-
dence demonstrated the phosphorylation of theNDUFA1 and
NDUFB11 accessory subunits in hamster (293) and NDUFA6,
NDUFA7, NDUFA10, NDUFA12, NDUFA13, NDUFB4,
NDUFB11, and NDUFC2 accessory subunits in bovine mito-
chondria (71, 201, 214). Although the functional consequences
of most of these subunit phosporylations are not yet fully
understood, studies regarding phosphorylation of the NDU-
FA1, NDUFB11, and NDUFS4 subunits in hamster have
provided some clues (203, 293). Mutational analysis of the
phosphorylation sites in the NDUFA1 (MWFE) and
NDUFB11 (ESSS) subunits revealed that mutation of MWFE
serine (S) 55 into a glutamate (E), glutamine (Q), or aspartate
(D) completely blocked CI assembly. The latter was not ob-
served when S55 was replaced with an alanine (A) residue.
Similarly, substitutions in the ESSS protein (S2A, S2E, S8A,
S8E, threonine (T)21A, T21E, S30A, and S30E) reduced CI
expression levels and activity. CI assembly was completely
blocked in an ESSS double mutant (S2=8A), suggesting that
MWFE and ESSS phosphorylation might affect CI activity.
In a variety of cell lines, CI activity increased and cellular
ROS levels decreased on stimulation of endogenous cyclic
AMP (cAMP) production or the addition of exogenous cAMP
(203). These effects were associated with protein kinase A
(PKA)-mediated serine phosphorylation of the conserved C-
terminus of NDUFS4. This phosphorylation promoted the
mitochondrial import and maturation of the NDUFS4 protein
inHeLa cells (61). It was proposed that phosphorylation of the
NDUFS4 subunit plays a role in maintaining optimal levels of
mature NDUFS4 protein for incorporation into CI. In this
way, the promoting effect of PKA could serve to increase CI
amount and activity. Interestingly, cAMP can be generated
inside the mitochondrial matrix by the carbon dioxide=
bicarbonate–regulated soluble adenylyl cyclase (sAC) in re-
sponse to metabolically generated carbon dioxide (3). This
pathway was demonstrated to serve as a metabolic sensor
modulating ATP generation and ROS production in response
to nutrient availability.
A number of scaffold proteins (e.g.,AKAP, PICK, Sab) have
been identified that bring specific kinases=phosphatases to
the cytoplasmic surface of the MOM (120). In higher eukary-
otes, modulation of the AKAP (A-kinase anchor protein)
complex regulates mitochondrial morphology and activity,
providing a mechanism to control signaling events at mito-
chondria (36). In Drosophila melanogaster, disruption of CI led
to a specific retardation of the cell cycle during G1-S transition
(198). It was demonstrated that the underlying signaling
consists of two independent pathways, one involving an in-
crease in AMP production and downregulation of cyclin E
protein, and a second one involving increased ROS levels and
upregulation of Dacapo, the D. melanogaster homologue of
human p27, a cyclin-dependent kinase inhibitor (Cdk) pro-
tein. This suggests that mitochondria can use signaling by
AMP and ROS at sublethal concentrations to modulate cell-
cycle progression.
1. Superoxide as a signaling molecule. In many studies,
ROS-induced damage and=or signaling were investigated by
using exogenous addition of H2O2 and=or ROS-generating
chemical or enzymatic systems. This approach increases ROS
throughout the cell (‘‘global ROS’’). However, when the ROS
are produced endogenously in healthy cells, the lifetime of a
certain ROS dramatically limits the distance it can diffuse
from its point of origin (‘‘local ROS’’). The average path length
or ‘‘Kuramoto length’’ (Dx) of a solute in an aqueous solvent is
given by
Dx¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
16
p
(D  s)
 s
¼ 2:26
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
(D  s)
p
(XIII)
with D and t being the diffusion constant and half-life of the
solute, respectively (104, 219, 230). For O·2 in water, D equals
5105 cm2·s1 (230), and t equals 106 s (101, 260). Substi-
tuting these values in Eq. XIII yields a value of Dx of
1.6105 cm, or 0.16 mm. Within a cell, however, O·2 is
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rapidly catabolized by antioxidants such as MnSOD (Fig. 12).
Moreover, it might react with nearby (bio)molecules. This
reactivity, as reflected by its affinity toward electrons
(Eh¼ 0.94V), is higher than that of H2O2 (Eh¼ 0.32V), but
much lower than that of OH· (Eh¼ 2.31V) (101). Additionally,
the mitochondrial matrix has a higher viscosity than water,
thereby slowing diffusion (144, 147). Therefore, in a cellular
environment, it is to be expected that the Dx for O·2 is (much)
smaller than 0.16 mm. In principle, a charged molecule like
O·2 will not pass theMIM, although under certain conditions,
VDAC seems to mediate the release of O·2 from the mito-
chondrion to the cytosol (113). Although O·2 can be proton-
ated, yielding the membrane-permeable perhydroxyl radical
(HO2
·) (230), this is not likely to occur in the mitochondrial
matrix, given its alkaline pH. Comparison of the small value
of Dx with the size of mitochondria (diameter*0.5–1mm; Fig.
1B) (144, 243) suggests that O·2 , when generated by CI under
physiologic conditions, does not leave the mitochondrion.
This idea is supported by the localized nature of spontaneous
bursts of O·2 generation in resting cardiacmyocytes, neurons,
and nonexcitable cells (‘‘superoxide flashes’’) (282). Individual
events were *10 s long and sharply spatially confined to
small elliptical areas, each spanning 0.94 0.01 mm (lateral)
and 1.68 0.03 mm (longitudinal), suggesting that each flash
was generated by a single mitochondrion. Interestingly, ETC
blockade at any site, as well as inhibition of CV, sufficed to
abolish O·2 flash activity. This suggests that an intact OX-
PHOS function is required for superoxide flash genesis (282).
It was proposed that, in analogy to localized Ca2þ signaling
(17), discrete O·2 flash events provide a potential frequency-
dependent mechanism for localized ROS signaling. In such a
mechanism, individual O·2 flashes would create micro-
domains of high (O·2 -derived) ROS, modulated by the action
of ROS scavengers, on top of a background of low cellular
ROS.
2. Hydrogen peroxide as a signaling molecule. In con-
trast to O·2 , H2O2 is freely diffusible through mammalian cell
membranes. Moreover, it has been proposed that diffusion
of H2O2 might be facilitated by specific channels (i.e., aqua-
porins) (21).This suggests that H2O2 concentrations in the
mitochondrion ([H2O2]m) and cytosol ([H2O2]c) are similar
during steady-state conditions (37). For H2O2 in water, D is
between 1105 and 2105 cm2=s (288), whereas t equals
105 s (101). Substituting these values in Eq. XIII yields a value
of Dx between 0.23 and 0.46 mm. In analogy to that of O·2 , the
Dx of H2O2 is reduced by the action of antioxidant systems
such as TrxR and=or GPx, its reactivity with (bio)molecules,
and matrix viscosity (Fig. 12).
In isolated resting rat liver mitochondria, [H2O2]m equaled
5–50 nM (29). During state 4 respiration (respiratory sub-
strates available, no ADP, a slow rate of O2 consumption),
0.6 nmol=min=mg protein of H2O2 was released into the ex-
tramitochondrial medium. This value decreased to 0.1 nmol=
min=mg protein during state 3 respiration (respiratory sub-
strates and ADP available, maximal rate of ATP produc-
tion and O2 consumption). In this latter situation, Dc was
significantly less negative, suggesting that a higher rate of
mitochondrial H2O2 production is associated with a more-
negative Dc. Extrapolated to a living cell, these results are
compatible with the idea that mitochondrial H2O2 might
serve as a metabolic homeostatic signal. Importantly, H2O2
signaling is concentration dependent (271). For example, in
human colon carcinoma (RKO) cells, the p53 transcription
factor activates antioxidant genes at a low sublethal [H2O2]
(0.2mM), but additionally, prooxidant target genes also be-
come activated when a higher [H2O2 ] (1mM) is used (227,
271). Another study revealed that low cellular [H2O2]
(i.e.,< 1mM) inhibits protein sumoylation, whereas an (un-
realistically) high [H2O2] (100mM) inhibits desumoylation
(28, 271). H2O2-mediated signaling has further been impli-
cated in the induction of antioxidant defense systems, cell
proliferation, cell differentiation, cell migration, apoptosis,
and aging (74, 101, 271).
3. Lipids as signaling targets of ROS. Oxidation of un-
saturated phospholipids diminishes membrane fluidity (92).
FIG. 12. Range of action of mitochondrial O2 and H2O2.
Superoxide (O2 ), generated inside mitochondria (e.g.,
by CI), is membrane impermeable and has a limited range
of action (Dx). O2 is converted into hydrogen peroxide
(H2O2), which is membrane permeable. However, H2O2
range of action is reduced by thioredoxin reductase-2 (TrxR)
and glutathione peroxidases (GPxs). This suggests that mi-
tochondrial O2 , and possibly H2O2, might act as local
regulators of mitochondrial morphology=motility and mito-
chondrial Ca2þ and ATP handling under physiologic con-
ditions. The vertical membrane bilayers reflect (from right to
left) the mitochondrial inner membrane, the mitochondrial
outer membrane, and the ER membrane. The latter mem-
brane is physically attached to the mitochondrial outer
membrane by proteinaceous tethers (black boxes) and might
be within the action radius of mitochondria-generated H2O2.
This figure is drawn to scale.
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As a consequence, lateral membrane protein diffusion is re-
duced, thereby promoting specific molecular interactions
(172). A likely local target of ROS is CL (see also Section IIE
and Section IIIB1), which is required in its nonoxidized form
for ETC supercomplex formation, optimal activity of ETC
complexes and mitochondrial transporters, the electrostatic
anchoring of cyt-c to the MIM, mitochondrial biogenesis, and
maintenance of MIM structure (47). Another major product of
lipid peroxidation, 4HNE, could also function as a signaling
molecule when generated at low levels (88, 209). Under these
conditions, 4HNE might induce reversible protein carbonyl-
ation (see Section IIIB2). In isolated mitochondria, 4HNE
stimulates MIM proton leak by activating mitochondrial un-
coupling proteins (UCPs). Because UCP opening appears to
reduce mitochondrial ROS production, it was postulated that
4HNE levels control mitochondrial ROS production. How-
ever, further study concerning the relevance of this mecha-
nism in living cells is required (5, 79).
4. Proteins as signaling targets of ROS. The function
of (membrane) proteins like ETC complexes can also be di-
rectly regulated by ROS. For instance, CI and a-KGDH not
only generate O·2 but also are reversibly inhibited by this
ROS (5). CI and a-KGDH activity and O·2 generation depend
on the intramatrix NADH=NADþ ratio. Accumulating evi-
dence (295) suggests that NAD(P)H andNAD(P)þ themselves
can function as signaling molecules in energy metabo-
lism, antioxidant regeneration (i.e., NADPH; Fig. 11), Ca2þ
homeostasis (e.g., through cyclic ADP-ribose and other mol-
ecules generated from NADþ and NADPþ), cell death (by
modulation of MPT, energy state, poly(ADP-ribose) poly-
merase 1, and apoptosis-inducing factor by NADþ and
NADPþ) and protein deacetylation (through NADþ-sensitive
sirtuins (see Section IIF ).
Inositol trisphospate receptors (IP3R) that release ionized
calcium (Ca2þ) from the endoplasmic reticulum (ER) on cell
stimulation also are sensitive to small changes in ROS con-
centrations and=or redox status (75).Moreover, functioning of
the SERCA pump, which transports Ca2þ from the cytosol
into the ER, is also affected by low ROS levels (118). This
connection between ROS and Ca2þ homeostasis is important
because Ca2þ represents the most common signal-transduc-
tion element that controls a wide array of cellular activities,
including secretion, contraction, and proliferation (17, 270,
286). Mitochondrial Ca2þ uptake and release is directly
involved in the regulation of cellular Ca2þ signaling and
stimulus-induced ATP generation. Proteins involved in trans-
MIMADP=ATP shuttling are ROS sensitive, possibly through
a CL oxidation-mediated mechanism (47).
With respect to local ROS signaling, it is very interesting
that a subpopulation of mitochondria is directly tethered to
the ER through interactions between (a) VDAC, the molecular
chaperone glucose-related protein 75 (grp75, a.k.a. mtHSP70)
and the IP3R on the ERmembrane (212), and=or (b) mitofusins
on the ER membrane and MOM (59, 60). As a consequence of
these interactions, (part of the) mitochondria and ER can come
as close as 10–25 nm (211, 223, 270). Therefore, is it conceivable
that mitochondrial ROS reach the ER membrane and func-
tionally affect IP3Rs, SERCA pumps and=or ER mem-
brane fluidity (Fig. 12). To add evenmore to the complexity of
this system, compelling evidence suggests that Ca2þ and ATP
also exert control over mitochondrial motility and morphol-
ogy (32, 229, 283, 294). This means that mitochondrial me-
tabolism and ROS generation, ER=cytosolic=mitochondrial
Ca2þ handling, mitochondrial=cytosolic ATP production, and
mitochondrial motility=structure are interconnected (14, 31,
35, 63, 145, 158, 213, 270, 287). The remainder of this review
discusses various aspects of this system in human skin
fibroblasts in the context of adaptive responses to rotenone-
(Section IVA) and mutation-induced CI deficiency (Section
IVB).
IV. Adaptive Responses to Complex I Deficiency
A. Adaptation to rotenone-induced complex I
deficiency in human skin fibroblasts
During recent years, we carried out a comprehensive
quantitative analysis of the cellular consequences of pro-
longed rotenone-induced CI inhibition (143, 145, 146, 272, 273,
286, 287). To this end, skin fibroblasts from healthy subjects
were cultured in the continuous presence of a low concen-
tration of the inhibitor (100 nM) for a duration of 72 h. Our
main findings are summarized in Fig. 13 and discussed with
respect to (a) mitochondrial Dc (Section IVA1), (b) mito-
chondrial and cytosolic redox homeostasis (Section IVA2), (c)
mitochondrial morphology and dynamics (Section IVA3), (d)
expression of mitochondrial proteins (Section IVA4), and (e)
mitochondrial and cellular Ca2þ and ATP handling (Section
IVA5).
1. Complex I activity and mitochondrial membrane po-
tential. Prolonged rotenone treatment reduced CI resid-
ual activity by 80% (142). This partial CI inhibition is essential
to prevent secondary rotenone toxicity associated with
(long-term) supramaximal inhibition of the enzyme (8). For
instance, we observed massive cell death when fibroblasts
underwent prolonged treatment with 5 mM rotenone (142),
demonstrating the inability of these cells to cope with high
inhibitor concentrations. This toxic effect is compatible with
the fact that high concentrations of rotenone are able to arrest
mammalian cells in metaphase by binding directly to tubulin
and preventing microtubule assembly (8). In this respect, it is
important to realize that none of the rotenone-induced effects
that we observed were paralleled by alterations in cell cycle,
cell death, or apoptotic features (142, 143, 145). The substantial
rotenone-induced reduction in CI activity induced only a
minor (10 to 15%) depolarization in Dc, as reported by mi-
tochondrial TMRM (tetramethyl rhodamine methyl ester)
staining (286). This is compatible with the lack of effect on Dc
in an R123-based assay when rotenone was briefly applied
(Fig. 10C). Similar results were obtained in 143B osteosarcoma
cells, in which, although rotenone-treated cells were unable to
generate ATP oxidatively, Dc was only slightly depolarized
when CI was inhibited for 3 days (8). We and others previ-
ously argued that, although the depolarization in Dc is only
small, it still might have substantial effects on the energy
homeostasis of the cell because the phosphorylation state of
the cytosolic ATP pool has been demonstrated to be very
sensitive to minor changes in Dc (68, 70, and the references
therein).
2. Redox homeostasis. Cells treated for prolonged pe-
riods with rotenone displayed an increased accumulation
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of fluorescent MitoSOX Red and HEt oxidation products
(Section IIIA1), compatible with increased O·2 production
(142, 272). Moreover, short-term addition of 100 nM rotenone
caused an immediate increase in the rate of Et formation,
indicating that the inhibitor acts instantaneously. Interest-
ingly, measurements made by using 5-(and-6)-chlor-
omethyl-20,70-dichloro-dihydrofluorescein diacetate (CM-
H2DCFDA), which is trapped intracellularly after its con-
version into nonfluorescent CM-H2DCF, revealed no in-
crease in the rate of ROS-induced formation of fluorescent
CM-DCF (145, 272). Although oxidation of CM-H2DCF to
CM-DCF was rapidly increased by short-term application of
H2O2 in living fibroblasts (148), it was not stimulated by
H2O2, Fe
3þ, glutathione peroxidase, and cyt-c in vitro. Con-
versely, in vitro CM-DCF formation was increased in the
presence of horseradish peroxidase, Fe2þ, CAT, CuZnSOD,
xanthine oxidase, ONOO, and NO·. This suggests that in-
tact cells contain catalysts, like transition metal ions, heme
peroxidases, CuZnSOD, or a combination of these, that
promote the H2O2-induced oxidation of CM-H2DCF. In this
respect, the rate of CM-DCF formation in cellular systems
can best be considered as a marker of oxidant levels rather
than as a direct reporter of a specific ROS=RNS species. The
fact that prolonged rotenone treatment increased O·2 pro-
duction without affecting CM-DCF formation indicates that
the O·2 -derived, CM-H2DCF–detectable oxidants are effec-
tively removed. Downstream of ROS formation, the levels of
cellular lipid peroxidation, assayed with the lipophilic re-
porter 148molecule C11-BODIPY581=591 (C11), were increased
in rotenone-treated cells (142). FRAP analysis of C11-stained
control cells revealed that C11 fluorescence recovered with a
half-maximal recovery time of 1.64 0.021min (n¼ 10 cells),
compatible with its presence in membranes.
Rotenone-treated cells also displayed an increase in
NAD(P)H autofluorescence and a small shift toward a more-
oxidizing mitochondrial=cytosolic thiol redox status, as
reported by the redox-sensitive GFP, roGFP1 (272). Brief
rotenone treatment dose-dependently increased NAD(P)H
autofluorescence in healthy fibroblasts, whereas treatment
with the mitochondrial uncoupler p-trifluoromethoxy car-
bonyl cyanide phenyl hydrazone (FCCP; 1mM) readily de-
creased this signal (272). Because rotenone inhibits substrate
oxidation by CI, NAD(P)H autofluorescence may reflect cel-
lular CI activity (286). To assess the relative contribution of the
GSSG=GSH couple in ROS removal and preserving of the
subcellular thiol redox environment, healthy fibroblasts were
cultured in the presence of 12.5 mM l-buthionine-(S,R)-
sulfoximine (BSO) for 72 h (272). BSO is a potent inhibitor of g-
glutamylcysteine synthetase, the rate-limiting enzyme in the
synthesis of GSH, and depletes the cell of GSH. It was ob-
served that BSO treatment dramatically increased the extent
of roGFP1 oxidation from 38% to 95% and from 20% to 77%
within the mitochondrial matrix and cytosol, respectively.
Moreover, this inhibitor caused a marked decrease in the rate
of HEt oxidation (50%), whereas, in sharp contrast, it sub-
stantially increased the rate of CM-H2DCF oxidation (50%). In
agreement with Fig. 11, the results obtained with BSO suggest
that the GSSG=GSH couple is important in the removal of
FIG. 13. Cellular consequences
of rotenone-induced complex I
deficiency. To study the cell bio-
logical effects of CI inhibition, skin
fibroblasts of a healthy subject
(#5120), were cultured in the pres-
ence of 100nM of the CI inhibitor
rotenone for 72h. This treatment
reduced CI biochemical activity by
*80% ( first column) and induced a
minor depolarization of Dc (second
column). Further quantification of
the effects of this treatment in-
volved cytosolic and mitochondrial
redox homeostasis, mitochondrial
morphology and dynamics, ex-
pression of key mitochondrial pro-
teins, and Ca2þ and ATP handling
in resting cells and in cells stimu-
lated with the hormone bradyki-
nin. *Different from vehicle-treated
control ( p< 0.05). **Different from
vehicle-treated control ( p< 0.01).
***Different from vehicle-treated
control ( p< 0.001). Numerals in the
bar graphs indicate the number of
cells or assays used to calculate the
average. Data for this figure were
compiled from (142, 144, 145, 273,
270, 286).
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CM-H2DCF-detectable oxidants in human skin fibroblasts.
The fact that HEt oxidation is proportionately reduced in
BSO-treated cells suggests that O·2 generation is decreased
and=or removal of O·2 is increased in GSH-depleted cells.
3. Mitochondrial morphology and dynamics. Quantita-
tive analysis of living cells revealed that the mitochondrial
formfactor (F), which is a measure of mitochondrial length
and degree of branching, was increased by chronic rotenone
treatment, whereas the number of mitochondria per cell (Nc)
was not affected (142,144). Interestingly, comparison of the
effect of prolonged CI inhibition onmitochondrial structure in
human skin fibroblasts and Chinese hamster ovary (CHO)
fibroblasts revealed that mitochondria became more ovoid in
CHO cells (Fig. 14). Therefore, at least for this parameter, the
effect of CI inhibition by rotenone is cell-type dependent. This
might relate to cell-type dependent differences in CI expres-
sion level (see Section IB), or to the fact that fibroblasts and
CHO cells are primary and cancer cell lines, respectively.
When human skin fibroblasts were co-cultured with rotenone
and 10nM of the MIM-targeted antioxidant MitoQ10 (186),
lipid peroxidation and mitochondrial shape alterations were
abolished, whereas the rate of Et formation remained elevated
(142). Importantly, 10 nMMitoQ10 alone did not affect the rate
of Et formation in these cells. Given its lipophilicity and
positive charge, MitoQ10 will first pass the plasma membrane
driven by the plasma membrane potential to accumulate
about fivefold in the cytosol. Then it will accumulate several-
hundred fold in the mitochondrial matrix in a Dc-dependent
manner. After its oxidation, MitoQ10 is reduced again by CII
to its active ubiquinol variant. MitoQ10 is not a good CI sub-
strate and cannot maintain respiration in mitochondria that
FIG. 14. Effect of prolonged rotenone-induced complex I inhibition on mitochondrial morphology in human skin
fibroblasts and CHO cells. (A) Skin fibroblasts of a healthy subject (#5120) cultured in the presence of 100 nM rotenone (ROT)
for 72 h and stained with rhodamine 123 (142). (B) Same as in (A), but now for Chinese hamster ovary (CHO) cells. (C) Effect
of long-term rotenone treatment on the mitochondrial aspect ratio (AR) and degree of branching (formfactor F) in human skin
fibroblasts. (D) Same as in (C), but now for CHO cells. COR, the background-corrected image; BIN, a binary version of the
same image obtained by image processing (68, 142, 146, 287). **Different from vehicle-treated ( p< 0.01); ***different from
vehicle-treated ( p< 0.001). Numerals indicate the number of cells that were analyzed.
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lack CoQ. The latter is because reduced MitoQ10 is poorly
oxidized by CIII (186). In isolated mitochondria, MitoQ10 is
rapidly taken up and preferentially adsorbed to the matrix-
facing leaflet of the MIM, with the triphenylphosphonium
moiety at the membrane surface at the level of the fatty acid
carbonyls, and the alkyl chain and ubiquinol moiety inserted
into the hydrophobic core of the lipid bilayer (186). The nor-
malization of mitochondrial shape and the degree of lipid
peroxidation by MitoQ10 in rotenone-treated cells suggests
that mitochondrial ROS-associated lipid peroxidation affects
mitochondrial shape and function, possibly through altering
mitochondrial membrane fluidity (172). Such an alteration
might, for instance, change the mitochondrial fission=fusion
balance by affecting Drp-1 cycling and=or Mfn2 interactions
(12, 14).
To allow quantitative assessment of the effect of rotenone
treatment on mitochondrial motility and intramatrix pro-
tein diffusion, we developed a novel approach to follow the
mobility of a matrix-targeted variant of GFP (mitoEYFP) in
living cells by means of fluorescence correlation spectros-
copy (FCS) (144, 147). FCS is a technique that measures in-
tensity fluctuations caused by single fluorescent molecules
moving through a small detection volume. By mathemati-
cally correlating these fluctuations, information can be ob-
tained about the concentration and rate of diffusion of the
fluorescent molecules. In contrast to the FRAP approach,
FCS requires only minute amounts of fluorescent proteins,
making it well suited to collect data under physiologic con-
ditions. Crucially, successful FCS analysis requires that mi-
toEYFP expression levels are not too high. To achieve the
latter, mitoEYFP was introduced into the cells by using a
modified (insect) baculoviral transfection approach (144,
147). FCS analysis revealed that the fraction of moving
mitochondria and their speed were reduced in cells cultured
in presence of 100 nM rotenone for 72 h. The intramatrix
diffusion of mitoEYFP, however, was increased in both sta-
tionary and moving mitochondria in rotenone-treated cells
(144). Other studies revealed that the mitochondrial matrix
adopts a more-condensed configuration when forced to
produce energy by oxidative phosphorylation (e.g., in ga-
lactose medium devoid of glucose), whereas during glycol-
ysis (e.g., in glucose medium), it is in a more-orthodox state
(12, 13, 171). Therefore, the faster intramatrix diffusion
in rotenone-treated cells could reflect that the fibroblasts
have switched to amore-glycolytic metabolism in an effort to
compensate for the loss in CI activity (144). As part of this
adaptation, ATP provided by glycolysis might be trans-
ported into the mitochondrial matrix by the ANT, where it
fuels CV running in reverse mode to sustain Dc (8, 144).
Spatial delivery of metabolites and energy will be most ef-
ficient in the case of lengthy, highly mobile mitochondria
with a continuous matrix exhibiting a fast translational dif-
fusion of solutes. This means that cells with elongated mi-
tochondria (i.e., rotenone-treated healthy fibroblasts) will
benefit far more from an increased matrix solute diffusion
than will cells with shorter mitochondria (i.e., untreated
healthy fibroblasts). Therefore, it appears that the increase in
the mitochondrial degree of branching and intramatrix
protein diffusion observed in rotenone-treated cells consti-
tutes part of an adaptive response to counterbalance the
detrimental effects of the decrease in CI activity (i.e., reduced
CI activity and mitochondrial motility).
4. Mitochondrial protein expression. At the protein level,
expression of the NDUFA9 subunit of CI (CI-39), as well as
the amount of fully assembled CI, was increased in cells
treated for a long period with rotenone (145, 273). This
suggests that the cell attempts to compensate for the reduc-
tion in CI activity by increasing the amount of complex.
Prolonged rotenone did not alter the protein amounts
of subunits CII-70, CIII-core 2, and CIV-II, suggesting
that the effect on CI was rather specific, as far as the
ETC complexes are concerned. Initial steps in CI assem-
bly, such as the formation of Sub-1 or the MIM-anchoring
of Sub-2 and Sub3 (Fig. 6), or both, might benefit from a
faster intramatrix protein diffusion (see Section IVA3),
thereby allowing more-rapid CI biogenesis. In contrast, an-
other study revealed no rotenone-induced change in
the expression of the ND1 subunit of CI (8). However,
this might be due to the use of another (cancer) cell type
(143B osteosarcoma cells) and the shorter incubation time
with rotenone (24 h vs. 72 h). Long-term rotenone treatment
also increased the expression of CV-a, VDAC, and mtHSP70
(a heat-shock protein present mainly in the mitochondrial
matrix). Increased expression of VDAC and mtHSP70 might
reflect mitochondrial biogenesis, compatible with increased
mitochondrial length and degree of branching, whereas
increased expression of CV would positively contribute to
the reverse-mode action of this complex to sustain Dc (see
Section IVA3).
5. Mitochondrial and cellular Ca2þ and ATP handling.
Proper cell functioning requires precise coordination be-
tween mitochondrial ATP production and local energy
demand (14, 17, 141, 252). Ionic calcium (Ca2þ) plays a cen-
tral role in this coupling because experimental and in silico
evidence suggests that it activates mitochondrial oxidative
phosphorylation (OXPHOS) in stimulated cells (150, 211,
270). To determine how rotenone-induced CI inhibi-
tion affected cytosolic and mitochondrial Ca2þ and ATP
handling, we quantified these parameters by using lumino-
metry and fluorescence-imaging microscopy (270, 274–276,
286).
Under resting conditions, the basal cytosolic [Ca2þ]
([Ca2þ]c), cultured in the presence of rotenone, was not altered
in fibroblasts from healthy subjects (286). This means that
although the cellular CI activity is greatly reduced, sufficient
ATP is produced to compensate for the continuous Ca2þ leak
into the cytosol from both the intracellular stores (mainly the
ER) and across the plasma membrane. In light of this obser-
vation, it was unexpected that the Ca2þ content of the ER
(ERCa) was significantly reduced in these cells (286). The
latter result points to a higher passive Ca2þ leak out of the ER
into the cytosol, a decreased intra-ER Ca2þ buffering capacity,
a reduced ATP-dependent Ca2þ uptake from the cytosol into
the ER, or a combination of these. Evidence was provided
that the reduction in ERCa was due to a decreased fueling of
its Ca2þ pumps by ATP from closely apposed mitochondria
(270, 286).
Extracellular stimulation of the cells with the hormone
bradykinin (Bk) subsequently induces (a) intracellular
production of inositol 1,4,5 trisphosphate (IP3), (b) activation
of the IP3R, and (c) release of Ca
2þ from the ER.
Compatible with the reduced ERCa observed in rotenone-
treated unstimulated cells, Bk stimulation induced a 15%
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lower peak increase in cytosolic and mitochondrial Ca2þ
concentration ([Ca2þ]c and [Ca
2þ]m, respectively) and a
23% lower peak increase in mitochondrial ATP concen-
tration ([ATP]m). Moreover, we observed that Ca
2þ was
32% more slowly removed from the cytosol after Bk stimu-
lation.
These findings led us to propose that the rotenone-in-
duced depolarization of Dc results in a decrease in oxidative
ATP production (8) and, consequently, a decrease in the
supply of the Ca2þ-ATPases of closely apposed intracellular
Ca2þ stores with mitochondrial ATP (286). Because of the
pump-leak nature of the Ca2þ stores, the resulting reduction
in active Ca2þ uptake leads to a decrease in ERCa. As a
consequence, subsequent stimulation with Bk results in
smaller increases in [Ca2þ]c, [Ca
2þ]m and [ATP]m. This then
leads to a reduced fueling with mitochondrial ATP of cyto-
solic processes that are stimulated by the increase in cytosolic
Ca2þ concentration, such as the active removal of Ca2þ from
the cytosol. Evidence supporting this mechanism was pro-
vided by using an intramitochondrial Ca2þ buffer, rhod-2,
which dose dependently decreased the Bk-induced increase
in [Ca2þ]m and [ATP]m and slowed the rate of cytosolic Ca
2þ
removal (276).
B. Adaptation to mutation-induced complex I
deficiency in patient fibroblasts
Comparing our results in rotenone-treated healthy fibro-
blasts (Fig. 13) with those observed in fibroblasts from a co-
hort of 16 patients with isolated CI deficiency (OMIM 252010)
due to mutations in nDNA-encoded subunits (Fig. 15), re-
vealed both striking similarities and differences (70, 143, 145,
267, 270, 272–276, 286, 287). Our cohort included patient cells
with mutations in NDUFS1 (one patient), NDUFS2 (five
patients), NDUFS4 (five patients), NDUFS7 (one patient),
NDUFS8 (two patients), and NDUFV1 (two patients). Patient
cells displayed a reduced residual CI activity that ranged
between 18% and 75% of the lowest control value for cells
carrying a mutation in the NDUFS8 (R94C) and NDUFS4 (a
K158 frame-shift) subunit, respectively (273). Importantly,
none of the changes in the patient cells described later were
due to differences in passage number or accompanied by
FIG. 15. Cellular consequences of inherited complex I deficiency. By using cultured primary skin fibroblasts from 16
patients with isolated CI deficiency due to mutations in nDNA-encoded CI subunits (NDUFV1, NDUFS1, NDUFS2,
NDUFS4, NDUFS7, and NDUFS8), we investigated the consequences of these mutations on 25 cellular parameters by using
quantitative life-cell microscopy. In all cases, residual CI activity was significantly below the lowest value obtained with
fibroblasts from healthy subjects. Importantly, for most parameters, the interpatient variation was large enough to allow us to
search for correlations by regression analysis. As in Fig. 13, we investigated primary effects, redox homeostasis, mitochon-
drial morphology and dynamics, protein expression levels, and calcium and ATP handling. Colors in the first column
indicate whether a certain parameter was ‘‘normal’’ (i.e., not significantly altered), ‘‘aberrant’’ (i.e., altered in most patients), or
‘‘variable’’ (i.e., altered in some cases) in the patient-derived cell line. The second column depicts the number of aberrant
patients. To highlight correlations between individual parameters (columns numbered 1–25), regression analysis was per-
formed with SPSS 15.0 by calculating bivariate correlations with Pearson’s correlation coefficient and two-tailed significance.
Colors are used to highlight significant positive (green) or negative (red) correlations. For clarity, data below the diago-
nal were not repeated above the diagonal. Data for this figure were compiled from refs. 69, 70, 143, 145, 272–275, 270, 286,
and 287. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this
article at www.liebertonline.com=ars).
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alterations in cell cycle, induction of cell death, or apoptotic
features (143, 145).
1. Similarities and differences with the rotenone model.
Similar to rotenone treatment of fibroblasts from healthy
subjects, CI mutations in patient fibroblasts were associated
with (a) a small though significant depolarization of Dc (10 of
10 patients) (70); (b) an increase inNAD(P)H autofluorescence
(nine of 10 patients) (286); (c) an increased rate of Et formation
(13 of 15 patients) (145, 273); (d) a normal number of mito-
chondria per cell (Nc; 10 of 16 patients) (143, 145); (e) a lower
resting ERCa (9 of 12 patients) (286); (f ) a normal resting
[Ca2þ]c (13 of 14 patients) (286); (g) a reduced peak [Ca
2þ]c (8
of 14 patients), peak [Ca2þ]m (7 of 12 patients), and peak
[ATP]m (9 of 14 patients) on stimulation with bradykinin (270,
286); (h) a slower cytosolic Ca2þ removal rate (10 of 14 pa-
tients) (270, 286); and (i) faster intramatrix protein diffusion in
moving mitochondria (2 of 2 patients) (147). The latter sug-
gests that the matrix of moving mitochondria is less dense in
the patient cells, allowing faster metabolite diffusion. As ar-
gued earlier, this is compatible with fibroblasts of CI-deficient
patients become more glycolytic, allowing a higher mito-
chondrial velocity (147).
In contrast to rotenone-treated fibroblasts from healthy
subjects, CI-deficient patient fibroblasts displayed (a) a de-
creased rather than increased amount of whole-cell NDUFA9
and mitochondrial fully assembled CI (8 of 10 patients) (145,
273); (b) an increased rate of CM-DCF formation (12 of 12
patients) (70, 145); (c) no significant alteration in mitochon-
drial and=or cytosolic thiol redox-status (10 of 10 patients)
(272); (d) no increase in lipid peroxidation (10 of 10 patients)
(272); (e) no increased expression of CV-a (10 of 10 patients)
and=or porin (10 of 10 patients); (f ) a similar rather than re-
duced fraction of motile mitochondria relative to control (2 of
2 patients) (147); (g) faster instead of slower mitochondrial
movement (2 of 2 patients) (147); and (h) normal instead of
faster protein diffusion in stationary mitochondria (2 of 2
patients) (147).
2. Validity of the rotenone model. We previously dis-
cussed the usefulness of the long-term rotenone model in
understanding human CI deficiency at the cellular level (145).
Comparison of Figs. 13 and 15 clearly demonstrates that
prolonged rotenone treatment of healthy fibroblasts does
not mimic the full spectrum of alterations observed in skin
fibroblasts derived from CI-deficient patients. Nevertheless,
the rotenone model is a valuable tool with which to study the
main consequences of and mechanisms involved in adapta-
tion to CI deficiency. The fact that rotenone induces several
features of Parkinson’s disease in humans and rats indicates
that results obtained with cellular rotenone models are also
likely to contribute to a better understanding of the patho-
physiology of this disease.
3. Mitochondrial morphology and dynamics. Prolonged
rotenone treatment induced an increase in mitochondrial
length and degree of branching without affecting the
number of mitochondria per cell. A similar change was
not consistently observed in CI-deficient patient fibroblasts
(142, 145). Quantitative analysis of these cells revealed that
mitochondrial morphology and number markedly dif-
fered between individual cell lines. Relatively large reduc-
tions in CI activity were associated with a reduced length
and degree of branching or an increased number of mito-
chondria per cells. This suggests a decrease in mitochondrial
mass or enhanced fission or both. Conversely, moderate
reductions in CI activity were found to be associated with an
increased length and degree of branching but never with a
decrease in the number of mitochondria per cell. The latter
clearly points to an increase in mitochondrial mass rather
than enhanced fusion.
To compare overall mitochondrial morphology between
cells, we introduced the operational parameter ‘‘mitochon-
drial complexity’’ (142, 145), which is given by the ratio be-
tween the mitochondrial length=degree of branching and the
number of mitochondria per cell. Patient fibroblasts could
be divided into two groups: one in which mitochondrial
complexity was significantly lower than that of the lowest
control (‘‘class I cells’’), and another one in which this value
was indistinguishable from control (‘‘class II cells’’). Un-
supervised cluster analysis of mitochondrial complexity and
biochemical CI activity revealed the same classes (145). On
average, class I cells had a lower mitochondrial complexity
than did class II cells, which was due to a significant decrease
in mitochondrial length=degree of branching and increase in
number of mitochondria per cell. Moreover, the average
amount of fully assembled CI and its residual activity were
significantly more reduced in class I cells than in class II cells,
suggesting that the degree of mitochondrial complexity and
CI deficiency are mutually dependent. Regarding the intra-
cellular levels of ROS, we observed that these were signifi-
cantly higher in cells with fragmented (‘‘low-complexity’’)
mitochondria (class I) as compared with cells with normal
(‘‘high-complexity’’) mitochondria (class II). Interestingly, by
using an inducible overexpression system (T-Rex HeLa Drp1
cells), we observed that Drp1-induced mitochondrial frag-
mentation, which reduced mitochondrial complexity by
25%, was not accompanied by a change in the rate of CM-
DCF formation (145). This suggests that mitochondrial
fragmentation does not generally lead to increased ROS
levels in this cell type.
4. Interrelationships between the cellular parameters. A
regression analysis was performed to highlight possible in-
terrelations between the parameters measured in patient fi-
broblasts (Fig. 15). Significant correlations were observed
between the ‘‘primary effects’’ (1 to 5) of inherited CI defi-
ciency (i.e., reducedCI activity, increasedNAD(P)H levels,Dc
depolarization, and increased rates of Et and CM-DCF for-
mation). This suggests that increased ROS generation and=or
insufficient ROS detoxification is a main consequence of in-
herited CI deficiency, in line with CI being an important
source of ROS in the living cell. The finding that rotenone
increased rather than decreased the amount of fully assem-
bled CI in control cells (Fig. 13) supports the idea that the
increased rates of Et formation observed in patient fibroblasts
result primarily from the reduction in cellular CI activity and
are not due to increased electron leakage from mutationally
malformed complexes (145).
The most simple explanation for Dc depolarization in the
patient fibroblasts would be that the CI-mediated proton
translocation capacity across the MIM is reduced in these
cells. However, given the correlation between the rate of
CM-DCF formation and Dc depolarization (Fig. 15), the
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latter also could result from a ROS-stimulated proton leak. In
such a mechanism, the small Dc depolarization might
function as a means to reduce mitochondrial ROS produc-
tion (72). The Dc and the resting ERCa2þ content displayed a
significant correlation (i.e., the less negative Dc, the lower
resting ERCa). Because Dc is an important determinant
for the rate of mitochondrial ATP production, this result is
in agreement with our rotenone data (Section IIIC5) and
supports the hypothesis that the (local) fueling of SERCA
pumps by mitochondrial ATP is reduced in resting patient
fibroblasts (70).
5. Effects of the antioxidant Trolox in patient cells. The
importance of ROS in the mechanism underlying the
mutation-induced changes in the cell physiologic parame-
ters is illustrated by the effects of the vitamin E derivative
6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid, or
Trolox (70, 148). Trolox is a phenolic antioxidant with a
chromane structure similar to that of vitamin E, but without
the polyisoprenoid hydrophobic tail. As a consequence, the
solubility of Trolox inwater (LogP¼ 2.8; see also Section IC) is
much higher than that of vitamin E (LogP¼ 10.7; source:
pubchem.ncbi.nlm.nih.gov), thereby facilitating its applica-
tion in live-cell studies. In vitamin E, its antioxidant action
appears to be exerted through the phenolic hydroxyl group,
which readily donates its hydrogen to, for instance, polyun-
saturated fatty acid peroxyl radicals, thereby forming a stable
lipid species. In this reaction, vitamin E is converted into a
relatively unreactive free radical, because the unpaired elec-
tron is delocalized into the aromatic ring. In vitro evidence
suggests that the Trolox radical can then be regenerated by
ascorbate, resulting in the formation of an ascorbyl radical.
Given the threefold lower LogP value of Trolox relative to
vitamin E, Trolox is probably less efficient in detoxification of
polyunsaturated fatty acid peroxyl radicals (see references
in 148).
Both brief and long-term (96-h) application of 0.5mM
Trolox decreased the rate of CM-DCF formation by*50% in
skin fibroblasts from a healthy subject (148). Addition of a
high concentration of H2O2 (1mM) increased the rate of CM-
DCF formation 23-fold in vehicle-treated cells but only 12-fold
in cells chronically treated with Trolox. These findings dem-
onstrate that Trolox is an effective antioxidant in human skin
fibroblasts. Analysis of patient fibroblasts revealed that pro-
longed Trolox treatment normalized the increased rates of
CM-DCF formation (148). Interestingly, long-term treatment
with Trolox markedly increased the amount and activity of
fully assembled CI in both healthy and patient fibroblasts.
This suggests that the total cellular CI activity is controlled by
the cell’s oxidative balance, primarily through regulation of its
amount. The effect of Trolox on Dc and Ca2þ=ATP homeo-
stasis is described in the next section.
6. Mitochondrial and cellular Ca2þ and ATP handling. At
the level of Ca2þ and ATP homeostasis and stimulus–
response coupling, results in CI-deficient patient cells were
generally similar to those obtained in rotenone-treated cells.
Therefore, it appears that the CI deficiency leads to a lower
ERCa in resting cells, most probably by reduced ATP fueling
of the SERCA pumps. Alternatively, ERCa in patient cells
might be reduced by functional impairment of these pumps or
IP3Rs or by increased ROS levels or both. However, maximal
SERCA-pump capacity in patient fibroblasts was normal (270,
286) and ERCa displayed a positive linear correlation with the
bradykinin-induced IP3R-mediated peak increase in [Ca
2þ]c,
disfavoring a role for IP3R malfunction (Fig. 15). Given
the established signaling role of Ca2þ in the ER lumen, the
reduced ERCa might affect intra-ER or cytosolic signal-
transduction pathways or both. In this respect, it has been
proposed that intra-ER Ca2þ not only functionally regulates
Ca2þ-binding chaperones responsible for intra-ER protein
folding, but also the expression of these chaperones once re-
leased from the ER by cell stimulation. Similarly, ERCa might
regulate proteins involved in ER-stress responses like the
UPR (unfolded protein response) and ERAD (ER-associated
degradation). To determine whether such mechanisms are
operational in CI-deficient patient fibroblasts, further inves-
tigations are needed. Strikingly, the number of mitochondria
per cell was negatively correlated to several other parameters.
With increasing mitochondrial number, CI activity decreased,
NAD(P)H levels and the rate of Et and CM-DCF formation
increased, the cytosolic thiol redox status became more oxi-
dized and expression of CII, CIII, CIV, and CV subunits was
reduced. This suggests that fragmentation of the mitochon-
drial network has detrimental consequences in human skin
fibroblasts. The latter is supported by the fact that the mito-
chondrial peak [ATP]m and cytosolic (ATP-dependent) Ca
2þ
removal rate during Bk stimulation, decreased as a function of
mitochondrial number within the patient cohort (Fig. 15). In
contrast, no correlation was observed between mitochondrial
length and degree of branching and peak [ATP]m and be-
tween mitochondrial length and degree of branching and
Ca2þ-removal rate. These findings suggest that differences in
mitochondrial length and=or degree of branching are not di-
rectly related to differences in Bk-stimulated Ca2þ and ATP
handling (287).
In addition to its effects on the rate of CM-DCF formation
and CI expression and activity (see Section IVB5), Trolox fully
restored Dc and ERCa in resting patient fibroblasts and nor-
malized cytosolic and mitochondrial Ca2þ and ATP handling
in Bk-stimulated patient fibroblasts (70). This suggests an in-
tegral role of increased ROS levels in CI deficiency and points
to the potential therapeutic value of antioxidant treatment.
An inhibitor of mitochondrial Naþ-Ca2þ exchange,
CGP37157, also normalized the Bk-induced increase in
[Ca2þ]m and [ATP]m, as well as the rate of cytosolic Ca
2þ
removal in CI-deficient patient fibroblasts (274). The effect of
CGP37157 was independent of the presence of extracellular
Ca2þ, excluding a stimulatory effect on Ca2þ entry across the
plasma membrane. These findings demonstrate that the mi-
tochondrialNaþ-Ca2þ exchanger is a potential target for drugs
aiming to restore or improve Ca2þ-stimulated mitochondrial
ATP synthesis.
7. The cell biological consequences of complex I deficiency.
Taken together, our results obtained with patient fibroblasts
suggest a model in which mutations in nDNA-encoded CI
subunits shift the balance between cellular ROS detoxification
and ROS production toward the latter situation. The magni-
tude of this shift is inversely proportional to the residual CI
activity and the amount of fully assembled CI (Fig. 15). When
ROS levels increase above a certain level, mitochondrial
fragmentation is triggered, which is prevented by Trolox.
Mitochondrial fragmentation is associated with reduced peak
COMPLEX I: BIOGENESIS, REGULATION, AND ROS 1459
values of [Ca2þ]m and [ATP]m during cell stimulation, lead-
ing to suboptimal SERCA fueling and slower cytosolic Ca2þ
removal. Although the reduced increases in [Ca2þ]m and
[ATP]m seem to originate primarily from a lower ER Ca
2þ
content, it remains to be established whether mitochondria
are less efficiently coupled to the ER in patient cells with a
high number of mitochondria (270). It is likely that the ele-
vated levels of ROS and NADH(P)H trigger the activation of
adaptive responses. This might be related to the observed
changes in mitochondrial shape, motility, intramatrix protein
diffusion, and mtHSP70 expression in rotenone-treated cells
andpatient fibroblasts. These alterationsmight reflect a switch
to a (more) glycolytic mode of ATP generation. The latter is
compatible with the normal resting [ATP]m and [ATP]c in
patient cells (270). Because no detectable differences in thiol
redox status, glutathione=glutathione disulfide content, or
extent of lipid peroxidation were observed in patient fibro-
blasts, the latter cells are able to maintain their thiol redox
status despite the marked increase in ROS production.
V. Conclusions
In living cells, the catalytic function of CI depends on (a) the
cellular amount of fully assembled CI protein, (b) its post-
translational modification (e.g., phosphorylation, acetylation),
(c) its binding to proteins and lipids, and (d) the in situ
availability of CI substrate in the form of NADH. CI amount
is determined by the balance between CI biogenesis and
degradation. Biogenesis of CI requires the time-coordinated
expression of its mtDNA- and nDNA-encoded subunits as
well as the action of proteins required for the import and
assembly of these subunits. It appears that CI is assembled in a
modular fashion within mitochondria, but it remains to be
demonstrated how CI assembly in the MIM is initiated, how
CI is degraded, andwhether itsmodules or subunits are stable
and can be recycled. In principle, CI can be considered an
input–output system that converts NADH (input) into NADþ
and PMF (outputs). In this respect, the control of CI biogen-
esis, degradation, and function by signaling pathways can
be regarded as means to modulate CI input–output behavior
(Fig. 16). Given the signaling role of NADþ and NADH, al-
teration of their concentration by CI action might allow au-
toregulation of CI input–output properties. We presented
evidence that CI constitutes a relevant ROS source within
healthy and patient cells. Depending on the nature and spa-
tiotemporal concentration of the generated ROS, which is af-
fected by the action of ROS-removing antioxidant systems,
oxidants can act as direct (local) regulators, longer-distance
redox signaling molecules, or inducers of oxidative stress. We
propose that CI-generated ROS might serve to control CI
function at the level of its biogenesis, stability (through lipid
peroxidation and=or attenuation of supercomplex formation),
and phosphorylation=acetylation in both healthy and patho-
logic conditions. This suggests that regulation of the CI input–
output system can also occur by ROS. As part of such a
mechanism, local action of mitochondrial ROS might allow
autoregulation of mitochondrial functioning and, as such,
give individual mitochondria the flexibility to respond au-
tonomously to local changes in intracellular environment and
metabolism. Future investigation of such a mechanism re-
quires experimental systems that allow the specific local
generation, detection, and removal of ROS.
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4HNE¼ 4-hydroxynonenal
ANT¼ adenine nucleotide translocator
CAT¼ catalase
CI¼ complex I
CL¼ cardiolipin
CoQ¼ coenzyme Q10 or ubiquinone
CuZnSOD¼ copper zinc superoxide dismutase
Cyt-c¼ cytochrome c
Dc¼membrane potential across the MIM
ERCa¼Ca2þ content of the ER
ETC¼ electron-transport chain
FCS¼fluorescence correlation spectroscopy
FeS¼ iron–sulfur
FMN¼flavin-mononucleotide
FRAP¼fluorescence recovery after
photobleaching
IMS¼ intermembrane space
IP3¼ inositol 1,4,5-trisphosphate
MIM¼mitochondrial inner membrane
MnSOD¼manganese superoxide dismutase
MOM¼mitochondrial outer membrane
MPT¼mitochondria permeability transition
MTS¼mitochondrial targeting sequence
NDUF¼NADH dehydrogenase ubiquinone
flavoprotein
NDUFAF¼NADH dehydrogenase ubiquinone
flavoprotein assembly factor
PMF¼proton motive force
PTP¼permeability transition pore
SERCA¼ sarco=endoplasmic reticulum Ca2þ
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TIM¼ translocase of the MIM
TOM¼ translocase of the MOM
VDAC¼voltage-dependent anion channel
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